



OPEN ACCESS

EDITED BY

Xiaoyun Mao,
The First Affiliated Hospital of China Medical
University, China

REVIEWED BY

Chitaranjan Mahapatra,
UMR5251 Institut de mathématiques de
Bordeaux (IMB), France
Shijing Wang,
China Medical University, China

*CORRESPONDENCE

William J. Tyler
✉ wjpt@uab.edu

RECEIVED 24 October 2025

REVISED 08 January 2026

ACCEPTED 12 January 2026

PUBLISHED 04 February 2026

CITATION

Do M and Tyler WJ (2026) Transcutaneous
vagus nerve stimulation in breast cancer:
a neuroimmune model to improve
quality of life.
Front. Oncol. 16:1731999.
doi: 10.3389/fonc.2026.1731999

COPYRIGHT

© 2026 Do and Tyler. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Transcutaneous vagus nerve stimulation in breast cancer: a neuroimmune model to improve quality of life

Melissa Do^{1,2} and William J. Tyler^{1,2*}

¹Department of Biomedical Engineering, University of Alabama at Birmingham, School of Engineering, Birmingham, AL, United States, ²Center for Neuroengineering and Brain Computer Interfaces, Heersink UAB School of Medicine, Birmingham, AL, United States

Breast cancer care has shifted beyond remission toward optimizing long-term physiological, emotional, and functional recovery. Many survivors continue, however, to experience persistent symptom clusters, such as insomnia, fatigue, anxiety, pain, depression, and cognitive impairment. These poor quality of life outcomes reflect underlying dysregulation of autonomic, neuroendocrine, and immune systems. Autonomic imbalance characterized by vagal withdrawal and sympathetic hyperactivation is linked to increased inflammatory load, impaired stress regulation, disrupted sleep, and poorer survival outcomes. Given the role of the vagus nerve in coordinating brain–body signaling and immune modulation, transcutaneous vagus nerve stimulation (tVNS) has emerged as a promising intervention to restore autonomic balance and attenuate psychophysiological burdens. Evidence suggests that tVNS modulates locus coeruleus–norepinephrine activity, regulates arousal and sleep, reduces fatigue and anxiety, enhances cognitive function, and activates the cholinergic anti-inflammatory pathways. Supported by mechanistic and clinical evidence, we propose tVNS as a precision-guided bioelectronic strategy for improving survivorship outcomes in breast cancer.

KEYWORDS

anxiety, autonomic regulation, breast cancer, fatigue, inflammation, insomnia, quality of life, vagus nerve stimulation

Introduction

Breast cancer is one of the most frequently diagnosed cancers globally, accounting for more than 2 million new cases a year (1). While treatment therapies have advanced significantly, disease and treatment consequences remain poorly addressed. Patients with breast cancer, beginning at diagnosis and into active treatment and survivorship, often endure persistent physiological and psychological symptoms such as insomnia, fatigue, anxiety, depression, pain, inflammation, and cognitive dysfunction (2–6). As a result, approximately 42%–45% of patients with breast cancer suffer from emotional distress, which has been formally recognized as the “sixth” vital sign because of its significant impact

of physical and psychological health (7, 8). These symptoms rarely occur in isolation but instead form interrelated clusters, often exacerbating one another and are associated with poorer treatment outcomes, elevated inflammatory markers, reduced treatment adherence, slower recovery, decreased overall health, and potentially reduced survival (9–11).

Breast cancer treatments, including surgery, chemotherapy, radiation therapy, and immunotherapy, further disrupt psychological resilience and distress, as well as the incidence of pain and inflammation (12). The most common treatment for breast cancer is surgery. Aside from fatigue, pain, and reduced mobility associated with surgery, changes in body image and self-perception following procedures like mastectomy can cause stress and depression (13, 14). Studies have shown that mastectomy is associated with increased severity of depression and anxiety, especially when compounded by the compromise of self-image (15). Similarly, the prevalence of depression was shown to increase in patients with breast cancer after chemotherapy (16, 17), radiation therapy (18, 19), and immunotherapy (14, 20). Symptoms can often persist after the cessation of treatment.

Women are often prescribed adjuvant hormone therapy for 10 years following primary breast cancer treatment to reduce cancer recurrence and mortality (21). Hormone therapy is extremely effective in inhibiting hormone production or by interfering with hormone receptor signals to prevent tumor growth when taken as prescribed (22). However, hormone therapy was reported to increase the risk or worsen depressive symptoms. The most common and severe side effects reported from hormone therapy treatment include sleep disturbances, fatigue, and depression, which have been associated with higher rates of depression (23). These adverse effects not only impair quality of life (QoL) but also serve as predictors of poor treatment adherence (24).

Despite its high prevalence and impact in patients with cancer, effective and systematic treatment interventions remain limited. Supportive and survivorship care serves to address these comorbidities, and while guidelines are well established, many patients in the United States report suboptimal results, leaving patients with cancer with persistent symptoms, unmet needs, poor coordinated treatment plans, and non-accessible comprehensive care (25–27). Primary providers often address many of these symptoms with pharmaceutical interventions such as benzodiazepines, non-benzodiazepine hypnotics, antidepressants, opioids, and non-pharmaceutical interventions such as cognitive behavioral therapy (CBT) (28–30). Pharmaceutical interventions, while effective, are often associated with risks of severe adverse effects and drug abuse or dependence (28, 31). Studies have shown that CBT is effective and long-lasting for a variety of mental and mood disorders. Despite this, up to 26% of patients prematurely drop from therapy (32). In addition, access to CBT is limited and underutilized (33). Although increasing awareness and substantial diagnosis and therapeutic advances have been made to address breast cancer, there remain unmet needs for addressing symptom clusters in patients with breast cancer.

Emerging evidence indicates that these symptom clusters reflect shared disruptions in autonomic and neuroimmune regulation,

marked by sympathetic overactivation, vagal withdrawal, and heightened inflammatory activity (2, 34, 35). Reduced heart rate variability (HRV), a validated biomarker of autonomic dysregulation and vagal tone, has been associated with increased inflammatory burden, impaired emotional regulation, decreased stress resilience, cognitive dysfunction, and reduced survival outcomes (36–39). Indeed, low HRV is frequently observed in patients with breast cancer and correlates with elevated circulating cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α), increased sympathetic drive, poorer QoL, and heightened mortality risk (37, 39). Collectively, this evidence positions autonomic dysregulation and inflammation as central mechanisms underpinning disease outcome and adverse symptom burden.

The vagus nerve sits at the center of psychophysiological regulation and may serve as a key mechanistic hub for therapeutic intervention in the QoL and survivorship in patients with breast cancer. As the primary component of the parasympathetic nervous system, the vagus nerve (cranial nerve X) provides extensive afferent and efferent innervation between the brain and visceral organs, including the heart, lungs, gastrointestinal tract, and immune system (Figure 1A). Afferent vagal inputs to the nucleus tractus solitarius (NTS) regulate the locus coeruleus–norepinephrine (LC-NE) system, modulate hypothalamic–pituitary–adrenal (HPA) axis reactivity, influence glucocorticoid sensitivity, and activate the cholinergic anti-inflammatory pathway (CAIP) (40–42). Through these networks, the vagus nerve governs arousal regulation, cardiovascular activity, stress resilience, emotional processing, cognitive function, immune tone, and systematic inflammatory signaling, all of which are domains disrupted in patients with breast cancer (Figure 1A). Furthermore, reduced vagal tone has been associated with increased risk of recurrence and poorer overall survival in breast cancer, suggesting that persistent neurophysiological distress may contribute to poor recovery and tumor-permissive biological states (37, 39, 43, 44).

Modern vagus nerve stimulation (VNS) began with the development of implantable devices in the late 20th century, with the first device approved for epilepsy in 1988 (45, 46). The success of invasive VNS in epilepsy management led researchers to explore its therapeutic potential across a range of conditions, and nearly 125 years after VNS was first described, non-invasive VNS emerged as a more accessible, lower-cost alternative (47). Today, transcutaneous vagus nerve stimulation (tVNS), embodied as transcutaneous auricular VNS (taVNS) targeting the auricular branch of the vagus nerve (ABVN) or transcutaneous cervical VNS (tcVNS) stimulating the cervical branch, has gained widespread attention for demonstrating safe and effective treatment in numerous conditions (Figure 1B). These tVNS approaches have been shown to treat depression, insomnia, migraine, chronic pain, posttraumatic stress disorder (PTSD), post-stroke rehabilitation, anxiety, epilepsy, and cognitive impairment (48–52). It is well established that VNS works, in part, by modulating the activity of the locus coeruleus (LC), a key noradrenergic nucleus within the ascending reticular activating system of the brainstem (53–56). This modulation drives cortical activation and regulates transitions across arousal states.




FIGURE 1

Afferent and efferent pathways of transcutaneous vagus nerve stimulation (tVNS) and their neuroimmune effects. (A) Schematic representation of auricular (taVNS) and cervical (tcVNS) stimulation targeting vagal afferents projecting to the nucleus tractus solitarius (NTS), with downstream modulation of the locus coeruleus (LC), dorsal motor nucleus (DMN), and norepinephrine (NE) release within central arousal and autonomic regulatory circuits. Efferent vagal signaling engages the cholinergic anti-inflammatory pathway, whereby acetylcholine (ACh) release activates $\alpha 7$ nicotinic acetylcholine receptors ($\alpha 7$ nAChR) on immune cells, reducing cytokine production and inflammation and promoting cellular recovery and tissue restoration. ACh, acetylcholine; DMN, dorsal motor nucleus; LC, locus coeruleus; NE, norepinephrine; NTS, nucleus tractus solitarius; taVNS, transcutaneous auricular vagus nerve stimulation; tcVNS, transcutaneous cervical vagus nerve stimulation; $\alpha 7$ nAChR, $\alpha 7$ nicotinic acetylcholine receptor. (B) Common methods of transcutaneous cervical vagus nerve stimulation (tcVNS) and taVNS are illustrated.

Through activation of NTS-mediated networks in humans, non-invasive stimulation of vagal sites has been shown to influence LC firing patterns and alter norepinephrine release throughout the brain, with downstream effects on arousal, attention, neural plasticity, emotional regulation, and autonomic balance (45, 52, 57–60).

Our recent open-label pilot study in women with breast cancer-related insomnia showed that nightly, bilateral taVNS is safe, well tolerated, and capable of improving sleep and psychophysiological outcomes, reinforcing its translational relevance for supportive and survivorship care (61). Early clinical studies across diverse populations further demonstrate the capacity for tVNS to improve symptoms in insomnia, anxiety, depression, pain, fatigue, and cognitive dysfunction, further supporting its potential as a psychophysiological regulator (49–51, 62). Taken together, tVNS presents a promising method for targeting the interconnected symptom clusters in patients with breast cancer through restoration of vagal tone, modulation of neuroimmune circuitry, and regulation of arousal pathways. Therefore, we propose a model that centers on the potential of tVNS to mitigate insomnia, fatigue, affective dysregulation, pain, and cognitive impairment by addressing autonomic and inflammatory dysregulation that impact the QoL

and survivorship in patients with breast cancer. By integrating current evidence from neuroscience, bioelectronic medicine, and psychoneuroimmunology, we present a conceptual and empirically grounded framework for incorporating tVNS into breast cancer treatment models to support patient disease recovery, survival, and improve physical, emotional, and mental distress.

Symptom clusters in breast cancer survivorship: a neuroimmune–autonomic perspective

Conceptualizing symptom clusters

Breast cancer and standard oncologic treatments can cause multisystem disruption across essential homeostatic regulatory systems, including those involved in immune activity, neuroendocrine signaling, and autonomic balance. These disruptions can impair treatment compliance, accelerate disease progression, and worsen clinical outcomes (2, 3, 63, 64). Over time, this dysregulation contributes to chronic fatigue, heightened

inflammatory activity, and reduced physiological resilience in patients and survivors (2, 64).


Cancer-related symptoms such as insomnia, fatigue, depression, anxiety, and pain are highly prevalent in breast cancer survivors and frequently co-occur rather than presenting as isolated complaints. The concept of symptom clusters demonstrates interdependent phenomena where individual symptoms often amplify one another, such that the presence of one increases the incidence and severity of others (Figure 2), ultimately compounding overall symptom burden (2, 64). Although these symptoms may present differently and emerge at various stages along the disease trajectory, they often share a common etiology that may be amenable to targeted intervention, thus gaining increased recognition in oncology research (65, 66).


Meta-analytical syntheses highlight that fatigue–sleep disturbance and psychological clusters, encompassing anxiety, depression, nervousness, irritability, sadness, and worry, are among the most consistently reported and burdensome symptoms in breast cancer populations (Figure 2). Additional empirical and meta-analytic evidence further indicates that fatigue–sleep disturbance and psychological symptom clusters (e.g., anxiety, depression, irritability, sadness, and worry) are the most frequently observed in patients with breast cancer (2, 5, 64, 67, 68). These symptom constellations form dynamic, interdependent networks rather than independent outcomes and suggest the presence of shared physiological drivers that sustain

chronic distress. Understanding symptom clusters can therefore guide the development of effective and integrated care strategies in women with breast cancer. Accordingly, research has increasingly focused on identifying symptom groups to develop strategies that can address multiple symptoms simultaneously (2, 3, 63, 64). This approach has the potential to optimize clinical efficiency, reduce healthcare burden, and improve QoL for patients by enabling more comprehensive and mechanism-informed symptom management.

Clinical burdens

Patients with breast cancer who present with high symptom clusters often report increased psychological distress, greater functional impairments, significantly lower rates of treatment adherence, and reduced health-related QoL compared to those with lower symptom clusters (11, 69, 70). Rather than emerging as distinct consequences of cancer treatment, these symptoms are increasingly recognized as manifestations of a shared underlying physiological disruption (Figure 3). Synergistic effects within clusters lead to cumulative cognitive-emotional load, decreased resilience, impaired daily functioning, and increased healthcare utilization (2, 71). In breast cancer survivors, sleep disruption and fatigue often precede and exacerbate affective dysregulation, which in turn amplifies pain perception and cognitive impairment (19,





72). These symptom clusters have been linked not only to diminished QoL but also to poorer overall survival and higher recurrence risk, underscoring the need for targeted interventions capable of addressing symptom burden (23, 73, 74).

Inflammation across clusters

Inflammatory processes appear to play a central role in the symptom cluster of sleep difficulties, fatigue, and depression (14, 75–77). Preclinical and clinical evidence supports pro-inflammatory cytokine release as a key mechanism in the development and persistence of cancer-related symptoms (66, 78, 79). Elevation of these cytokines has been associated with fatigue, depressive and anxiety symptoms, pain, and cognitive impairment in breast cancer populations (72, 80, 81), as well as with tumor progression, metastasis, and poorer prognosis (82, 83). Furthermore, pro-inflammatory cytokines contribute to sleep fragmentation and prolonged sleep latency, promote energy depletion via mitochondrial dysregulation, enhance nociceptive signaling, and trigger “sickness behavior” phenotypes characterized by fatigue, negative mood, reduced motivation, and cognitive slowing (81, 84). Chronic inflammation is associated with impaired executive function, reduced attentional control, and deficits in working memory (85). This multifaceted cytokine involvement supports the hypothesis that inflammatory amplification is not incidental but functions as a mechanistic convergence point that underlies symptom cluster expression. Given this well-established link between cancer and inflammation, targeting inflammatory modulation presents a compelling pathway for mitigating symptom burden in patients with breast cancer.

Autonomic dysregulation and reduced vagal tone across clusters

Converging evidence suggests that autonomic dysregulation, characterized by reduced vagal tone and increased sympathetic activation, not only influences tumor biology and immune function but also emerges as an underlying mechanism that permits symptom clustering in patients with breast cancer (2, 35, 37, 39, 86). Decreased vagal activity disrupts key inhibitory mechanisms over sympathetic arousal and inflammatory activation via the CAIP (Figure 3). This results in increased norepinephrine signaling and β -adrenergic stimulation of immune cells, promoting the transcription of pro-inflammatory cytokines including IL-6, TNF- α , and C-reactive protein (CRP) (86, 87), which are associated with fatigue, sleep disruption, mood disorders, pain, and cognitive impairment (81, 88). Indeed, persistent low vagal tone has been identified as a predictor of higher inflammatory load, greater fatigue, poorer sleep quality, and increased emotional distress in cancer populations, implying that autonomic imbalance plays a fundamental role in long-term psychophysiological and QoL outcomes (72, 73).

HRV-based studies demonstrate that greater vagal withdrawal correlates with increased cluster intensity across symptom cluster networks (2, 37). This autonomic profile is recognized in patients with breast cancer, where higher HRV, indexing increased vagal tone, predicts decreased tumor burden, treatment adherence, and longer survival (37, 38). Breast cancer survivors with insomnia, fatigue, depression, and pain consistently demonstrate lower HRV compared to healthy controls, indicating diminished parasympathetic influence (34, 39, 87, 89–93). Within this

framework, symptom clusters are reflections of conceptualized chronic autonomic and inflammatory dysregulation. This model supports a therapeutic strategy aimed at restoring vagal tone and rebalancing autonomic function to simultaneously reduce systemic inflammation and improve multi-symptom burden.

It is important to note that parasympathetic nervous system stimulation (via the vagus nerve) has been hypothesized to lead to decreases in the production of pro-inflammatory cytokines through the release of acetylcholine (86). In general, activation of the sympathetic branch of the ANS leads to increased inflammation and activation of the parasympathetic branch leads to decreased inflammation (94). Indeed, studies have documented cross-sectional associations between higher parasympathetic activity, as indexed by HRV, and lower levels of inflammation (95–97). Taken together, these observations support an autonomic nervous system (ANS) framework as a unifying mechanism in breast cancer-related symptoms. This framework will be used as a recurring interpretive lens throughout subsequent sections to contextualize the autonomic, inflammatory, and neurocognitive mechanisms underlying individual symptom clusters.

A dysfunctional psycho-neuroimmune loop

These symptom clusters appear to be sustained and permitted by recurrent feedback loops involving autonomic dysregulation, inflammatory signaling, affective processing, and cognitive appraisal (Figure 2) (98). For example, psychological distress related to breast cancer frequently emerge or intensify during cancer treatment and may persist long after its treatment ends. Chronic behavioral and psychological comorbidities, combined with the side effects of primary and adjuvant treatments, markedly increase the risk of insomnia, while sleep disturbances further exacerbate this distress and increase inflammatory cytokine expression (99). In turn, fatigue and anxiety are heightened. Fatigue reduces activity levels, which leads to increased pain sensitivity and negative affect. Negative affect further disrupts sleep and cognitive processing, perpetuating the cycle (67, 100).

Breast cancer is also associated with dysfunction across multiple biological systems, including immune, endocrine, and neurological pathways, which further contribute to the onset and persistence of these symptom clusters (14, 77). As previously established, inflammatory processes play a central role in the symptom cluster of sleep difficulties, fatigue, and depression, while poor sleep has been consistently associated with elevated inflammatory markers (4). Studies have shown that insomnia in cancer populations is strongly associated with elevated rates of depression and anxiety (18), as well as impaired immune function. Indeed, depression in breast cancer survivors can emerge through several etiological factors, including psychological stressors, physiological dysfunction, and treatment side effects. Diagnosis is life-altering and often gives rise to significant psychological and emotional distress, including a sense of crisis, uncertainty about prognosis, financial burdens, fear of recurrence, and disruption to a patient's sense of normalcy (101). To reiterate, these symptoms may present

differently and emerge at various stages along the disease trajectory but often co-exist and share etiological underpinnings. Studies report that as many as 90% of patients diagnosed with depression complain of sleep disturbances and poor quality of sleep (102), and individuals with insomnia are over four times more likely to develop depression (103). Risks and severity of mental health increases with disease severity and the presence of symptoms such as pain, fatigue, and sleep disturbances (23). Evidence of comorbidity and reciprocal interactions reinforce a chronic psychophysiological stress state that is resilient to single-symptom therapeutic approaches.

Rationale for vagal intervention

Breast cancer-related symptom cluster burden may therefore be conceptualized as a state of altered neuroimmune homeostasis, where dysregulation of ANS function interacts with persistent immune activation to maintain symptom clusters (Figure 2, Table 1). Studies show that higher inflammatory burden and lower vagal tone jointly predict worse fatigue, sleep efficiency, depressive affect, and cognitive complaints in survivors (35, 73). This has led to growing interest in neuromodulatory interventions targeting autonomic restoration, particularly therapies that enhance parasympathetic (vagal) activity, to interrupt inflammatory signaling and ameliorate symptom clusters (86, 104). Such approaches offer a mechanistic alternative to symptom-specific treatments by addressing synergy and overlap in neuroimmune-autonomic circuits (Figure 3). Non-invasive VNS is uniquely positioned to engage afferent vagal circuits, shift autonomic balance, reduce inflammatory signaling through CAIP activation, and recalibrate neural systems involved in arousal, emotional regulation, pain processing, and cognitive function [(Figure 3, 58, 104–106)]. Therefore, tVNS represents a theoretically grounded, neuromodulatory approach to treating psychophysiological burden in patients with breast cancer. This sets the stage for a mechanistic exploration of how tVNS may intersect with each symptom domain.

Psychophysiological clusters: inflammatory and autonomic mechanisms

Insomnia and hyperarousal: cytokine activation, dysregulated arousal, and sympathetic dominance

Insomnia is one of the most prevalent and debilitating symptoms reported by patients with breast cancer, often persisting for years following treatment (107). Patients with breast cancer report the highest rates of insomnia and fatigue compared to other cancer populations, with prevalence estimates ranging from 38% to 70% (12, 108). Sleep deprivation and poor sleep quality is a critical concern for breast care clinicians because it is associated with poorer treatment outcomes, slower recovery, increasing risk of

disease progression, decreased overall health, and potentially reduced survival (18, 63, 109). A case-control study that examined sleep quality and duration in women with advanced sleep cancer found that patients with breast cancer who experience greater sleep disturbances show higher mortality rates compared to those who report better sleep quality (110). Moreover, poor sleep quality in patients with breast cancer are associated with increased stress and depressive symptoms, decreased immune function, impaired cognitive functioning, reduced memory consolidation, and deteriorated physiological health (111–114). These symptoms can significantly compromise mental, emotional, and physical functioning, potentially leading to negative personal, professional, and social consequences and reduced QoL (Colten, 2006; Ho, 2015). This is particularly concerning in vulnerable populations who face cumulative health risks and multifaceted disorders (63, 109). The systemic nature of these effects suggests that insomnia in patients with breast cancer reflects deeper physiological dysregulation, particularly involving autonomic imbalance and inflammatory activation (Table 1).

Sleep disturbance is closely linked to hyperarousal, inflammatory activation, and disrupted autonomic regulation (2, 4). Breast cancer survivors exhibiting insomnia often show reduced HRV, indicating diminished vagal tone and heightened sympathetic dominance, signatures consistent with physiological hyperarousal (Table 1 (39, 91); Inflammatory mediators such as IL-6, TNF- α , and CRP further exacerbate arousal, disrupt sleep regulatory circuits, and reinforce sympathetic dominance (80, 115, 116). These cytokines can interfere with sleep-wake modulatory pathways by promoting glial activation and altering neuromodulatory signaling in hypothalamic and brainstem pathways involved in sleep consolidation and circadian

regulation (117, 118). Indeed, elevated levels of pro-inflammatory cytokines are associated with increased sleep latency, higher wake after sleep onset (WASO), and reduced slow-wave sleep (80, 116, 119, 120).

Autonomic dysregulation further contributes to insomnia pathophysiology. The ANS is a control system for homeostatic functions and visceral adjustments that are involved in secretory activities that mediate sleep (121). Neuroanatomical studies demonstrate that sleep-wake regulatory nuclei are closely integrated with regions governing autonomic function, suggesting that ANS is integrally related to sleep physiology (122). In addition, sleep disorders are often reported as manifestations of symptoms of autonomic impairment (57). Indeed, extensive literature supports the role of the ANS in modulating cognitive processes across sleep and arousal biology (57, 120, 122, 123). When this regulatory balance is disrupted, sleep disturbance can trigger sympathetic overactivation and reduce vagal tone, initiating a state of physiological hyperarousal and autonomic imbalance (57). Even transient disruptions in sleep can increase sympathetic drive and inflammatory signaling, perpetuating an autonomic-inflammatory feedback loop that perpetuates hyperarousal and impairs autonomic function (120). To the extent that sleep architecture exerts direct effects on autonomic regulation, autonomic dysfunction may conversely induce sleep disturbances, regardless of the underlying etiology.

Insomnia is increasingly conceptualized as a disorder of hyperarousal, characterized by elevated tonic LC-NE firing, sympathetic dominance, reduced vagal tone, and persistent activation of wake-promoting systems that resist transition into sleep (119, 124). This imbalance drives increased cortical arousal, sustained activation of the HPA axis, and excessive catecholaminergic

TABLE 1 Mechanisms and biomarkers of burdensome symptom clusters in breast cancer.

Symptom cluster	Neuroimmune mechanisms	Psychophysiological (arousal) mechanisms	Key biomarkers
Insomnia and sleep disturbance (hyperarousal)	Inflammatory activation disrupts sleep regulatory circuits. Chronic stress and reduced vagal input promote tonic locus coeruleus-norepinephrine (LC-NE) overactivation.	Physiological hyperarousal. Sympathetic dominance and reduced vagal tone. Sustained activation of wake-promoting systems.	Reduced heart rate variability (HRV) indexing weakened vagal tone. Elevated interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- α), and C-reactive protein (CRP).
Anxiety and depression (affective dysregulation)	Elevated inflammatory tone. HPA axis dysregulation (e.g., elevated catecholamines and cortisol) is triggered by chronic stress. High chronic cytokine levels increase depressive and anxiety symptoms.	Autonomic imbalance and sympathetic dominance. Vagal withdrawal limits the capacity for emotional regulation. Chronic sympathetic activation and dysregulated LC-NE signaling worsen anxiety.	Lower HRV (associated with diminished emotional regulation). Elevated IL-6, TNF- α , and CRP. Dysregulated cortisol rhythms.
Cancer-related fatigue (CRF)	High inflammation load driven by autonomic dysregulation. Proinflammatory cytokines (e.g., CRP, IL-6, and TNF- α) correlate with greater fatigue severity.	Reduced vagal tone and shift toward sympathetic dominance. Weakened inhibitory control over inflammatory pathways due to disrupted cholinergic anti-inflammatory pathway (CAIP) reflex.	Lower high-frequency heart rate variability (HF-HRV). Elevated IL-6 and TNF- α . Flattened diurnal cortisol rhythms.
Pain and nociceptive amplification	Inflammatory processes sustain pain by causing cytokine-driven nociceptive sensitization. Cytokines such as IL-1, IL-6, and TNF- α contribute to central sensitization and increased nociceptor excitability.	Autonomic dysregulation. Increased sympathetic tone enhances nociceptor sensitization. Impaired vagal tone reduces inhibitory descending pain modulation.	Reduced HRV (correlated with heightened pain intensity). Elevated IL-6, TNF- α , and IL-1 β .
Cognitive impairment	Chronic inflammation is associated with impaired executive function and reduced attentional control. Pro-inflammatory cytokines trigger brain fog or cognitive slowing.	Chronic distress and low parasympathetic tone promote tonic LC-NE overactivation (hyperarousal), which contributes to cognitive impairment.	Decreased HRV. Diminished pupillary reactivity or pupillary dilation (as scalable proxies of tonic LC firing and cognitive effort).

output, reinforcing difficulty initiating and maintaining sleep (39). Chronic stress and reduced vagal input promote tonic firing of the LC, which is associated with sustained wakefulness, vigilance, and cognitive hyperarousal (40). In contrast, optimal sleep–wake cycling requires a shift toward phasic LC firing and vagally mediated deactivation of hyperarousal circuits. Thus, insomnia in patients with breast cancer reflects a broader dysregulation of the central autonomic and neuroimmune networks, positioning interventions that recalibrate autonomic balance, suppress excessive arousal, and modulate inflammatory signaling, such as tVNS, as mechanistically relevant therapeutic strategies (Figure 3).

Anxiety and depression: neuroimmune–HPA imbalance and vagal withdrawal

Patients with breast cancer face an elevated risk of anxiety and depression compared to both the general population and individuals with other types of cancer (125–127). Prevalence estimates vary, with studies reporting depressive symptoms in 20%–30% of patients (128). A large-scale study of 59,340 women revealed that breast cancer survivors had a 39% increased risk of depression compared to healthy controls (129). Globally, the prevalence of depression in patients with breast cancer has been reported to be as high as 30.2% (130). Anxiety prevalence is similar with one study reporting that approximately 32% of patients with breast cancer were diagnosed with anxiety (127). In a more recent study that included 283 patients with breast cancer, depression, anxiety, and stress prevalence were high (46.6%, 56.9%, and 51.9%, respectively) (131).

Depression in patients with breast cancer has been linked to poorer clinical outcomes, including lower QoL, reduced adherence to treatment, and increased risks of recurrence and mortality (132–134). A prospective study of 578 women with early-stage breast cancer reported that depressive symptoms, particularly hopelessness and high scores on the Hospital Anxiety and Depression (HAD) scale, significantly predicted reduced 5-year survival (135). In support, more recent studies associated pre-diagnosed depression with a 26% higher risk of death and post-diagnosed depression with a 50% higher risk of death (136).

Depression and anxiety in breast cancer survivors can emerge through several etiological factors, including psychological stressors, physiological dysfunction, and treatment side effects and is strongly correlated with autonomic imbalance and heightened inflammatory tone (5). Breast cancer can disrupt immune, endocrine, and neurological function, increasing the risk of depression through neurobiological changes such as reduced monoamine transmission, HPA axis dysregulation, impaired neuroplasticity, and chronic inflammation (137, 138). Chronic stress, perceived threat, and emotional distress trigger sustained activation of the HPA axis, resulting in elevated CRH signaling, and catecholamine levels that promote neuroinflammation and impair negative feedback regulation (81, 139). Reduced vagal tone limits capacity for emotional regulation, impairing adaptive engagement of prefrontal–limbic circuits that normally constrain stress

reactivity and anxiety-driven hypervigilance (140, 141). Consistent with this model, lower HRV is associated with diminished emotion regulation capacity, increased depressive symptoms, and decreased stress resilience (39, 91).

Chronic sympathetic activation and dysregulated LC-NE signaling worsen anxiety symptoms, while HPA axis dysregulation maintains elevated cortisol levels that contribute to mood destabilization and glucocorticoid resistance (81). Concurrently, vagal withdrawal and heightened sympathetic tone reduce inhibitory control over inflammatory pathways, leading to increased concentrations of pro-inflammatory cytokines such as IL-6, TNF- α , and CRP, which have been strongly implicated in the development and persistence of anxiety and depressive symptoms (142, 143). Elevated cytokines can also alter monoaminergic signaling, particularly within the LC-NE system and serotonergic circuits and further increase depressive phenotypes via neuroimmune mechanisms (144). Thus, anxiety and depression in breast cancer survivors reflect a pathophysiological state characterized by HPA axis dysregulation, increased inflammation, sympathetic dominance, and impaired emotional regulation circuitry, reinforcing one another through chronic neuroimmune feedback loops (Figure 2, Table 1).

Pain and nociceptive amplification: cytokine sensitization and autonomic dysregulation

Pain is a frequent and often persistent symptom among breast cancer survivors, arising from a combination of treatment-related tissue damage, central sensitization, and immune-driven nociceptive amplification (71). Inflammatory cytokines such as IL-1 β , IL-6, and TNF- α contribute to both peripheral and central sensitization by increasing nociceptor excitability, facilitating spinal dorsal horn hyperactivity, and altering descending pain modulation pathways (81, 145). Persistent inflammation may shift pain from an acute tissue-damage response to a sustained neuromodulatory dysfunction wherein sensitized pain pathways remain hyperreactive even in the absence of peripheral input (146).

Autonomic dysregulation can exacerbate pain, particularly neuropathic pain, in cancer survivors. Increased sympathetic tone enhances adrenergic receptor-mediated sensitization of nociceptors and lowers pain thresholds in response to sensory stimuli (147). Conversely, impaired vagal tone reduces inhibitory descending pain modulation via brainstem pain pathways, including the NTS, decreasing engagement of endogenous anti-nociceptive mechanisms (91). Indeed, reduced HRV is associated with heightened pain intensity and pain-related distress in cancer survivors, suggesting that parasympathetic withdrawal contributes to dysregulated nociception (91, 147–150). Collectively, pain in patients with breast cancer reflects a convergence of cytokine-driven nociceptive sensitization and autonomic imbalance that fails to adequately recruit anti-nociceptive and anti-inflammatory control systems. This autonomic–inflammatory imbalance contributes not only to pain chronicity but also to co-occurrence with fatigue, anxiety, sleep disturbance, and depressive symptoms.

Cancer-related fatigue: neuroimmune exhaustion and blunted vagal signaling

Cancer-related fatigue (CRF), defined by the National Comprehensive Cancer Network as a distressing, persistent, and functionally impairing sense of physical, emotional, or cognitive exhaustion disproportionate to activity (151), affects 60%–90% of patients with breast cancer and survivors across treatment phases (84). CRF is linked to poorer QoL and may be a predictor of shorter survival in patients with breast cancer (89). Rather than a passive consequence of treatment burden, CRF is now recognized as a multidimensional exhaustion state driven by dysregulated psycho-neuroimmune and metabolic systems (Figure 3).

One proposed mechanism underlying CRF in patients with breast cancer is elevated inflammation driven by autonomic dysregulation (67, 72, 73). Indeed, studies have shown an association between elevated inflammatory markers and fatigue (152). Elevated proinflammatory cytokines such as IL-6 and TNF- α are correlated with greater fatigue severity (72), while breast cancer survivorship studies demonstrate persistent CRF in individuals with autonomic imbalance, sleep-wake disruption, and elevated inflammatory biomarkers (145). Reduced vagal tone and a shift toward sympathetic dominance exacerbate CRF by disrupting the CAIP reflex, leading to insufficient $\alpha 7$ nicotinic acetylcholine receptor-mediated suppression of pro-inflammatory cytokines, thereby sustaining a state of neuroimmune activation and central fatigue signaling (35, 86). Autonomic imbalance further perpetuates CRF by weakening vagally mediated anti-inflammatory control and promoting sympathetic overdrive. In breast cancer survivors, lower high-frequency HRV has been directly associated with greater fatigue severity and elevated inflammatory markers such as IL-6, supporting the model that autonomic imbalance facilitates cytokine-driven neuroimmune fatigue loops (35, 89). Flattened diurnal cortisol rhythms and glucocorticoid receptor resistance contribute to dysregulated energy homeostasis and heightened fatigue perception (72).

Mechanistic overlap across clusters

The psychophysiological clusters observed in patients with breast cancer share overlapping inflammatory and autonomic mechanisms that create self-reinforcing cycles of distress. Across symptom domains, we synthesize that elevated cytokines disrupt sleep architecture, promote depressive mood, increase nociceptive sensitivity, and heighten fatigue, while poor sleep, pain, and affective symptoms further increase inflammatory output. Sympathetic overactivation contributes to hyperarousal in insomnia, anxiety-driven vigilance, enhanced pain perception, and increased metabolic demand, while vagal withdrawal impairs emotional regulation and reduces activation of the CAIP. Chronic distress and low parasympathetic tone also promote tonic LC-NE overactivation, amplifying hyperarousal, disrupting sleep/wake cycles, and fostering physical and mental fatigue (40).

These converging mechanisms form interdependent psychological neuroimmune loops in which insomnia increases inflammation and emotional dysregulation, fatigue reduces activity levels and increases depressive symptoms, and anxiety heightens stress reactivity and autonomic dysfunction [Figure 3, (67, 98)]. The persistence and mutual reinforcement of these physiological symptoms and what underlies it may help explain why many standard single-symptom treatments produce only transient relief (2, 64). Therefore, interventions capable of recalibrating autonomic balance, dampening inflammatory signaling, and modulating arousal may offer a pathway for simultaneous alleviation of multiple symptom domains (Figure 3, Table 2).

Given that autonomic and inflammatory dysregulation collectively shape the emergence and maintenance of these symptom clusters in patients with breast cancer, the vagus nerve, which exerts regulatory influence over LC-NE activity, arousal, emotional control circuits, and the CAIP, emerges as a compelling therapeutic target for psychophysiological symptom cluster relief.

TABLE 2 Proposed advantages of transcutaneous vagus nerve stimulation compared to standard-of-care treatments of symptom clusters in breast cancer.

Standard-of-care (SOC)	SOC limitations	Proposed advantages of tVNS
Pharmaceutical interventions (e.g., benzodiazepines, opioids, and antidepressants)	Associated with risks of severe adverse effects, drug interactions, and drug abuse or dependence.	Is a non-pharmacologic adjunct that has demonstrated safety and tolerability, with common adverse events being only mild and transient (e.g., skin irritation and headache).
Cognitive behavioral therapy (CBT)	Access is limited and underutilized. Patients prematurely drop from therapy.	Is safe, well tolerated, and feasible for repeated use in outpatient and home settings, making it suitable for long-term integration into survivorship care.
Single-symptom treatments	Often produces only transient relief because breast cancer symptoms are sustained by interconnected neuroimmune feedback loops.	Is a circuit-level intervention uniquely positioned to target multiple symptoms (clusters) simultaneously through up- and downstream stream modulation of autonomic balance and anti-inflammatory pathways.
Implanted vagus nerve stimulation (VNS)	Requires surgically invasive procedures that present added stress and immune challenges. Can produce off-target side effects (e.g., sleep apnea and dysphonia).	Is non-invasive and offers accessibility and ease of use, positioning it as a potentially viable first-line intervention compared to surgically implanted VNS devices.

Transcutaneous vagus nerve stimulation

tVNS has emerged as a promising non-invasive neuromodulatory approach capable of modulating ANS activity, inflammatory and immune signaling, cardiovascular activity, digestion, and brain networks involved in cognition, arousal, and mood (48, 57, 104, 106, 153–155). Given some potential advantages over other treatment methods (Table 2), tVNS has gained increasing clinical interest over the last decade. The taVNS approach is grounded in anatomical evidence demonstrating that the ABVN innervates specific regions of the external ear, particularly the tragus, cymba concha, concha, antihelix, and external acoustic meatus (156). Stimulation at these sites is theorized to elicit therapeutic effects comparable to those achieved through implanted VNS (51, 157, 158). Likewise, tcVNS targets the cervical trunk of the vagus nerve at the neck using surface electrodes placed over the sternocleidomastoid region, though its deeper anatomical location may result in less selective activation of vagal fibers (51, 60, 159). Both approaches have been shown to modulate key neuroimmune and autonomic pathways underlying symptom clusters across the cancer trajectory.

Central pathway of VNS through the NTS

Although taVNS and tcVNS differ in their anatomical stimulation sites, both modalities primarily recruit vagal afferent pathways and converge on central mechanisms that are characteristic to vagus nerve activation (Figure 1A). Pivotal *c-fos* mapping studies provided some of the earliest neuroanatomical evidence identifying the central structures engaged by VNS. *C-fos* immunostaining studies in rats using stimulation parameters comparable to those used clinically for epilepsy (500 μ s, 30 Hz, 1 mA, 30 s on/5 min off for 3 h) demonstrated widespread activation of vagal afferent-related regions, including the NTS, LC, cochlear nucleus, posterior amygdaloid nucleus, cingulate and retrosplenial cortices, hypothalamic nuclei, and the habenular nucleus (160). Subsequently, functional neuroimaging and electrophysiological studies confirmed overlapping activation of the NTS, LC, amygdala, insula, and prefrontal cortex, indicating that VNS primarily modulates autonomic–limbic–arousal control circuits (58, 60, 105). VNS primarily activates afferent fibers that project to the NTS in the medulla, a key autonomic integration center (60, 106). From the NTS, ascending projections innervate key neuromodulatory centers, including the LC, parabrachial nucleus, dorsal raphe, amygdala, hypothalamus, and PFC, modulating arousal, affective regulation, autonomic output, and inflammatory tone (40, 41, 161). Through these circuits, tVNS can influence several psychophysiological domains central to breast cancer-related symptom clusters.

One of the principal neurophysiological systems influenced by VNS is the LC-NE system. Historically, the LC-NE system has been implicated in arousal, but more advanced observations suggest that this system is involved in regulating a broader range of brain

functions and processes including autonomic activity, attention, memory, and sensory processing (162). LC exhibits two essential types of neural discharges (tonic and phasic) that modulate cognition and behavior in response to sensory or environmental cues. Based on experimental observations in monkeys, neurons in the LC have been shown to undergo shifts in response to sensory discrimination and cognitive focus. Neurons of the LC tonically fire at high frequencies when tasks demand focused attention or during hyperarousal. Likewise, LC neurons tonically fire at low frequencies when engagement levels are low. In addition, transient firing burst preceded behavioral shifts by activating the release of NE across the brain, demonstrating LC activity support in arousal, attention, and behavioral flexibility (40, 161, 163).

The well-characterized firing patterns of the LC and its regulation of NE release are closely linked to autonomic regulation and vagal tone. LC elicits NE and acetylcholine release that act to sharpen neural signal-to-noise ratio to boost alertness to meaningful stimuli and increase arousal and emotional resilience, while concurrently activating vagal pathways that clamp overactive sympathetic arousal (164). Indeed, VNS has gained attention for its ability to safely modulate ANS activity, inflammation, neuroplasticity, attention, mood, and arousal (54, 57, 106, 154). In states of chronic stress, fatigue, and hyperarousal, the LC shifts toward high tonic firing, which promotes anxiety, insomnia, cognitive impairment, and dysfunctional allostatic stress responses (40). Disrupting high-frequency tonic firing in the LC enables the transition from high-frequency tonic LC activity to low-frequency tonic LC activity, boosting phasic LC-NE activity, a pattern linked to improved alertness, mood regulation, and sleep-wake stability (40, 161, 163, 164). VNS has been shown to modulate autonomic balance by attenuating LC tonic hyperactivity, an established driver of insomnia, hyperarousal, anxiety, and fatigue, while restoring more adaptive phasic responsiveness, contributing to improved attentional control and sleep initiation (54, 161). Through this mechanism, tVNS may offer an alternative to standard therapies by counteracting LC-driven hyperarousal that underlies persistent insomnia, anxiety, and emotional distress frequently reported in patients with breast cancer (Table 2).

In early studies, vagal afferent stimulation induces EEG synchronization via NTS-LC pathways, reflecting a shift toward lower tonic LC firing and increased alpha-theta activity (165, 166). Increased alpha-theta activity is linked to a shift toward parasympathetic nervous system dominance, indicating a relaxed and calm state (167). Moreover, high-frequency (tens of kHz) transcutaneous trigeminal and vagal stimulation attenuates sympathetic reactivity by modulating noradrenergic pathways, as demonstrated by reduced salivary α -amylase (an NE biomarker), suppressed galvanic skin conductance, increased skin temperature via sudomotor relaxation and vasodilation, and decreased subjective stress during shock-induced fear conditioning in healthy adults (153). Following this initial dampening of sympathetic tone, a shift toward parasympathetic dominance emerges, a sequence supported by pupil dilation studies demonstrating reduced arousal-related pupillary responses (153, 155). More investigations over the last decade have shown that both tcVNS and taVNS can reduce the

sympathetic nervous system activity, as well as the psychological and neurophysiological symptoms of stress (168–172).

HRV is a well-established marker of autonomic function, reflecting the dynamic balance between sympathetic and parasympathetic nervous system activity (141, 173, 174). Numerous studies have demonstrated that higher HRV is associated with reduced sympathetic arousal, increased vagal tone, and greater physiological resilience to stress (59). VNS has been shown to improve HRV, reflecting enhanced parasympathetic control and better overall autonomic regulation (59, 175). It is also worth noting that high vagal activity, as indexed by elevated HRV, has been associated with improved prognosis and increased survival across multiple cancer types, including breast cancer, due to vagal-mediated decrease inflammation (50). Given that HRV is responsive to vagal stimulation and since it plays a predictive role in general health outcomes, we propose that it can be utilized as a key biomarker to advanced personalized tVNS approaches in breast cancer (Table 3, Figure 4).

Beyond its modulation of LC-NE tone, VNS engages broader limbic and autonomic networks that contribute to affective and stress regulation. Afferent input to the NTS activates the dorsal raphe and enhances 5-HT signaling, while LC projections to the amygdala and hypothalamus recalibrate emotional responsiveness and arousal intensity (176, 177). tVNS further strengthens prefrontal–amygdala connectivity, facilitating top-down emotional control (178), and modulates HPA activity by dampening


corticotropin-releasing hormone release and normalizing cortisol rhythms (142, 179). These central effects are complemented by enhanced cortical–autonomic coupling and increased HRV, supporting greater physiological flexibility under stress (147). In addition, VNS has been shown to reduce HPA axis excitability, a key stress pathway implicated in chronic depression (57), while also enhancing amygdala–dorsolateral prefrontal cortex connectivity, which supports improved emotional regulation (154). The HPA axis governs the body’s stress response via cortisol secretion, exerting immunosuppressive effects (180). Evidence in mice and human models demonstrate that the VNS can downregulate HPA axis hyperactivity and elicit anti-inflammatory effects via the NTS and the paraventricular nucleus (PVN) (181–184). Additionally, animal studies indicate that VNS may enhance neuroplasticity and alter neuronal firing patterns, further contributing to its antidepressant potential (185).

Cholinergic anti-inflammatory pathway and cytokine suppression

In parallel with its central neuromodulatory effects, VNS also recruits descending parasympathetic efferent projections arising from the nucleus ambiguus and dorsal motor nucleus of the vagus, which increase vagal tone, suppress sympathetic dominance, and enhance high-frequency heart rate variability

TABLE 3 Components of a precision tVNS approach to the treatment of individualized symptom clusters in breast cancer.

Component	Biomarker-informed framework	Rationale
Patient stratification (phenotyping)	Patients are categorized into distinct subgroups based on measurable biological and psychological data prior to intervention (phenotyping).	Symptom clusters reflect shared underlying autonomic and inflammatory dysregulation. Stratification addresses the heterogeneity of psychophysiological and quality of life burdens.
Biomarkers used for stratification	Autonomic markers: Heart rate variability (HRV), inflammatory cytokines: IL-6, TNF- α , C-reactive protein (CRP), arousal/sleep indices: EEG, pupillometry, psychomotor vigilance, reactivity, actigraphy, and cortisol slope.	Low HRV (vagal withdrawal) identifies high-yield target groups for tVNS, particularly those with hyperarousal-related insomnia and anxiety. Elevated cytokines identify a “high-cytokine phenotype” potentially needing CAIP-engaging protocols to suppress chronic inflammatory signaling. Arousal markers act as scalable proxies of tonic vs. phasic locus coeruleus (LC) firing.
Phenotype-based targeting	Patients are matched to intervention strategies targeting their dominant drivers. For example: Hyperarousal-insomnia phenotype (characterized by reduced HRV and tonic LC overactivation); inflammatory fatigue phenotype (characterized by elevated IL-6 and CRP, as well as brain fog).	This approach addresses breast cancer distress as a cluster-based syndrome (e.g., insomnia–fatigue–anxiety constellations) rather than disconnected complaints, moving toward cluster-stratified deployment.
Dosing strategy (personalization/adaptivity)	Personalized tVNS delivery is implemented through individualized stimulation parameters in an open- or closed-loop manner.	This framework aims to optimize therapeutic engagement and adoption.
Parameters to individualize	Modality: taVNS vs. tcVNS. Frequency, pulse parameters, and duration. Timing: e.g., morning vs. daytime vs. pre-sleep administration. Intensity: Must be administered between perceptual and pain thresholds to avoid sympathetic arousal.	Dose–response studies are essential for defining optimal parameters for specific symptom constellations. Closed-loop systems dynamically adjust parameters based on real-time physiological sensing (e.g., HRV, sleep state transitions, and pupillometry) to align with patient-specific psychophysiological states.
Clinical endpoints (symptom outcomes)	Validated measures assessing the entire symptom cluster (not isolated domains).	Symptom domains include sleep disturbance, fatigue (cancer-related fatigue), anxiety, depressive symptoms, pain interference, and cognitive function.
Mechanistic endpoints (biological validation)	Parallel assessment of biological markers post-intervention to confirm mechanism engagement.	Mechanistic endpoints include changes in HRV (vagal tone restoration); reduction in IL-6, TNF- α , and CRP (CAIP engagement and cytokine suppression); and normalization of cortisol slope (HPA axis recalibration).



(HF-HRV), a marker of autonomic restoration (59). A cornerstone of this influence is engagement of the CAIP, a vagally mediated inflammatory reflex arc in which efferent vagus nerve activation stimulates acetylcholine release via splenic nerve interactions, thereby activating $\alpha 7$ nicotinic acetylcholine receptors on macrophages and monocytes and suppressing systemic inflammation through reduced production of pro-inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 (42, 86, 143). Under conditions of chronic inflammation, elevated CRP levels can induce a feed-forward loop that drives sustained tonic LC activity, contributing to hyperarousal, impaired attentional filtering, and sleep disruption, hallmarks of disorders such as PTSD and major depressive disorder (186, 187).

Both invasive and transcutaneous VNS have demonstrated its ability to suppress systematic inflammation and reduce circulating levels of pro-inflammatory cytokines in clinical and preclinical models of systemic inflammation (188–195), accompanied by improvements in systemic immune tone, fatigue, nociceptive sensitization, and sickness-related behavior (42, 50, 59). Given that inflammatory cytokines are mechanistically implicated in sleep fragmentation, pain amplification, cognitive slowing, negative affect, and CRF, CAIP activation represents a critical pathway through which tVNS may disrupt symptom clustering in breast cancer by simultaneously restoring parasympathetic dominance and suppressing chronic inflammatory signaling (80, 81). Although the anti-inflammatory potential of VNS has not been systematically studied in breast cancer populations, its efficacy in modulating immune function in other clinical contexts warrants further investigation to address cancer-related inflammation and its downstream effects on sleep, fatigue, and QoL in patients with breast cancer. Furthermore, discrete and continuous monitoring of cytokine levels should be included as key biomarkers in efforts to personalize tVNS therapies (Table 3, Figure 4).

Stimulation parameters, comfort, and feasibility in survivors

Both taVNS and tcVNS have been shown to be safe, well tolerated, and feasible for repeated use in outpatient and home settings, making them suitable candidates for long-term integration into breast cancer survivorship care (51, 52, 62). These devices typically use electrical currents through surface electrodes, with customizable intensities based on sensory thresholds. Although taVNS is still in its infancy, literature illustrating safety considerations and parameters for clinical use suggest a consensus that current intensity should be administered between perceptual and pain thresholds to control for nociceptive discomfort that can lead to confounding effects (104, 196). Neuroanatomical evidence of mixed innervation in the ear and physiological studies show that painful or uncomformable stimulation can recruit non-vagal nociceptive fibers associated with sympathetic arousal, particularly A δ and C fibers from the auriculotemporal nerve or the great auricular nerve (156, 197–199). Additionally, pain or discomfort are known to decrease vagal activity and is a distracting confound that can cause emotional distress during use, potentially affecting sensory processing and influence the efficacy of taVNS (147, 149, 177). Direct evidence for tVNS-induced pain on efficacy is limited, but strong anatomical and physiological rationales suggest that it is critical that tVNS does not induce discomfort or pain as it may cause significant compounds, especially in enhancing brain plasticity, modulating arousal, and optimizing human performance (177).

Comfort and adherence consider factors such as skin sensitivity, electrical sensation tolerance, device portability, and ease of application. A systematic review of 51 studies (total $N = 1,322$) found that tVNS was safe and well tolerated in humans at the doses tested. The most common adverse events were mild and transient (e.g., skin irritation ~18%, headache ~3.6%) and no serious adverse events were definitively attributed to the intervention (49). Cancer

survivors may particularly benefit from tVNS due to its minimal invasiveness, lower discomfort levels, and suitability for fatigue or insomnia-focused interventions. Personalized titration based on baseline HRV, inflammatory burden, or predominant symptom cluster may enhance response, although responder phenotyping remains an evolving area of investigation (105).

The clinical and physiological effectiveness of tVNS is highly dependent on several factors including some key stimulus parameters: frequency, intensity, pulse width, and duty cycle. These parameters can vary widely across research and clinical applications. Stimulus intensity in taVNS typically ranges from 0.1 to 50 mA, though most studies use intensities below 6 mA (200, 201). Because individual skin impedance and sensitivity differ, different dose titration methods are used in studies. These include methods for setting the intensity at individual perceptual thresholds (the lowest level at which a sensation is detected), just at the comfort thresholds (strong but comfortable), or at a fixed multiple of the threshold (e.g., 200% of perceptual threshold) (200–202). The type of electrode interface utilized includes titanium or steel ball electrodes, Ag/AgCl disks, and conductive silicones affixed to the external ear or hydrogel earbud systems designed to interface with the walls of the external acoustic meatus (106, 199). Because of electromechanical and human factors and variables discussed elsewhere, these interfaces will differentially affect patient comfort and adoptability (106).

Stimulation frequency is another critical factor, shaping the temporal pattern of neural firing and influencing clinical outcomes. Frequencies from 3 to 80 Hz are most common in clinical practice. For example, 1–5 Hz is used for migraine and gastrointestinal disorders, while 10–25 Hz is standard for conditions like major depressive disorder, anxiety, epilepsy, and insomnia. Higher frequencies, such as 30 Hz, are applied for cardiovascular regulation and Parkinson's disease. Medium to high frequencies (100–900 Hz) have shown benefits for chronic pain, insomnia, and cognitive performance (54, 177, 203–205). Very high frequencies (1,000–20,000 Hz) are used in sub-perceptual protocols to reduce sensation while still achieving therapeutic effects, such as in rheumatoid arthritis and peripartum depression (206–208). Neuroimaging studies indicate that these high frequencies up to 20 kHz can induce lasting changes in brain connectivity without the user perceiving any electrical sensation (207). Sub-perceptual dosing, often at high frequencies > 300 Hz set at 75%–80% of the perceptual threshold, can be used to ensure participants feel no sensation, which is particularly useful for blinding in clinical trials (106).

While most taVNS protocols favor left-ear stimulation for historical reasons, evidence indicates that right-sided or bilateral stimulation can be safely implemented to enhance or differentially modulate outcomes (177, 209–212). Technical implementation of tcVNS frequently utilizes handheld devices that deliver a waveform consisting of five 5-kHz sine wave bursts, each lasting 1 ms, which repeat at a rate of 25 Hz (213). Unlike taVNS where lower intensities are required to achieve efficacy, tcVNS necessitates much higher current dosages to penetrate the skin and reach the deep-seated cervical trunk, with peak output currents reaching up

to 60 mA. Based on recent modeling and empirical observations, the general tcVNS approach has been revealed to involve a high degree on nonspecific nerve and muscle stimulation that can cause off-target effects (214). Thus, we recommend that investigators and clinicians carefully and critically evaluate tVNS methods and parameters available to select approaches that safely meet the needs of their desired study or intervention objectives. Furthermore, future research should focus on how different parameters like stimulus frequency, duration, and intensity affect specific outcomes like inflammatory responses. These observations will help advance both open- and closed-loop approaches to personalizing tVNS therapies (Figure 4).

Effects of transcutaneous vagus nerve stimulation on symptom cluster outcomes across clinical indications

Inflammation

There has been a recent surge in the use of tVNS for immunomodulation across several chronic inflammatory and stress-related conditions. In autoimmune disorders like rheumatoid arthritis, tcVNS has been shown to significantly reduce CRP and interferon-gamma (IFN- γ) levels in patients with high disease activity (215). Similarly, in patients with psoriatic arthritis, tcVNS produced a 20% reduction in CRP, while those with ankylosing spondylitis exhibited decreases in IFN- γ , IL-8, and IL-10 (216). Beyond musculoskeletal conditions, taVNS has been demonstrated to reduce proinflammatory cytokines in constipation-predominant irritable bowel syndrome (217) and promote an anti-inflammatory monocyte phenotype in patients with metabolic syndrome (218). Furthermore, tcVNS effectively blocks the stress-induced activation of IL-6 and IFN- γ in patients with PTSD (213), while taVNS inhibits mental stress-induced cortisol release, suggesting a potent inhibitory effect on the HPA axis (182).

In acute neurovascular and systemic inflammatory states, taVNS serves as a non-invasive method for mitigating deleterious immune responses. Following subarachnoid hemorrhage, taVNS has been found to significantly reduce TNF- α and IL-6 in both plasma and cerebrospinal fluid, which correlates with reduced radiographic vasospasm and improved clinical outcomes (219). In the context of acute ischemic stroke involving large vessel occlusion, taVNS significantly lowered IL-6 levels, with additional reductions noted in IL-1 β and IL-17 α (220). The modality has also been applied to critical care and systemic infections, where it reduced cytokine production in sepsis (188) and improved inflammatory markers in patients with COVID-19 (221). Following lung lobectomy, taVNS has been shown to significantly decrease serum concentrations of CRP and IL-6 while elevating the anti-inflammatory cytokine IL-10 on the first postoperative day (189). Even in healthy volunteers, taVNS has demonstrated systemic efficacy by attenuating the whole blood transcriptomic inflammatory response to a lipopolysaccharide (endotoxin)

challenge, underscoring its potential as a scalable approach for immunomodulation (211). Collectively, these findings warrant future investigations examining how tVNS affects immune responses to breast cancer and cancer therapies.

Insomnia

Data from several randomized, sham-controlled studies show that tVNS is useful for improving chronic insomnia. In a multicenter randomized controlled trial (RCT) ($N = 72$), Zhang et al. (210) reported clinically meaningful reductions in sleep quality scores after 8 weeks of taVNS, with benefits sustained throughout the 20-week study period compared to sham. A more recent double-blind RCT ($N = 40$) likewise found that sleep quality scores improved significantly in chronic insomnia disorder after 6 weeks of taVNS, along with a significant increase in QoL (222). We recently conducted a pilot study exploring the effects of nightly taVNS on insomnia in patients with breast cancer ($N = 20$). We found that 2 weeks of bilateral taVNS targeting the external acoustic meatus with hydrogel earbud electrodes, used each night for 15 min prior to bedtime, significantly reduced insomnia index scores, improved sleep quality, decreased sleep onset latency, and enhanced sleep efficiency as observed through biometrics and patient-reported outcomes (61). In addition, we observed significant reductions in the number of nightly awakenings, CRF, and depression, while increasing HRV (61). Future tVNS development efforts should use data acquired through biometric devices in precision medicine embodiments to individualize treatment plans and programs based on sleep quality, activity patterns, and HRV (Table 3, Figure 4).

Anxiety and depression

There is growing evidence showing that tVNS can significantly improve depressive and anxiety symptoms. A 2023 systematic review and meta-analysis of 12 RCTs ($N = 838$) showed that taVNS is effective and safe for depressive disorder, with response rates comparable to antidepressants in mild to moderate cases (223). In a randomized clinical trial in patients with MDD, taVNS was directly compared to citalopram, a selective serotonin reuptake inhibitor. The results showed that taVNS was as effective as citalopram and led to higher remission rates (224). Beyond primary MDD, a double-blind, sham-controlled RCT in post-stroke depression reported significant improvements with taVNS versus sham, reinforcing antidepressant effects across etiologies (225). In another double-blind RCT, taVNS treatment was shown to reduce anxiety through modulation of autonomic and affective circuits, aligning with improved parasympathetic tone and LC-NE arousal regulation (226). In our pilot study evaluating the effects of nightly taVNS in patients with breast cancer, we found that it produced significant reductions in depressive symptoms, while increasing HRV (61). More broadly, tVNS targeting sympathetic

hyperarousal is reported to reduce anxiety symptoms and depressive symptoms in stress-related disorders, including PTSD (227) and for treatment-resistant depression (196). While trials in broader populations are warranted, current evidence supports tVNS as a tolerable, non-pharmacologic adjunct for depression and anxiety.

Pain and nociceptive disorder

The strongest human evidence base for tcVNS is in migraine and cluster headache, with multiple RCTs showing acute pain relief and/or reduced attack frequency versus sham (45). In fact, tcVNS is Food and Drug Administration (FDA) approved for migraine and cluster headaches, supported by these randomized, sham-controlled trials showing significant reductions in headache frequency, attack duration, and pain intensity (228, 229). In a multicenter RCT of chronic migraine, tcVNS significantly reduced monthly migraine days compared to sham, with high tolerability (230). Beyond headache disorders, taVNS has been shown to reduce pain sensitivity and improve functional pain outcomes in conditions such as fibromyalgia, chronic musculoskeletal pain, and neuropathic pain, with associated increases in vagal tone and decreases in pro-inflammatory cytokines (231, 232). More specifically, taVNS has been shown to significantly reduce neuropathic pain associated with radiofrequency therapy in patients with head and neck cancer (233). Similarly, another study has demonstrated that taVNS can significantly reduce pain associated with chemotherapy-induced peripheral neuropathy in patients with cancer while improving sleep and QoL (193). Collectively, these findings support tVNS as a promising neuromodulation approach for pain relief in patients with breast cancer.

Cancer-related fatigue

Several studies show that tVNS represents a promising therapeutic approach for alleviating fatigue symptoms across multiple clinical contexts. For example, in patients with systemic lupus erythematosus, a double-blind RCT pilot study found that taVNS significantly reduced both pain and fatigue scores compared to sham stimulation, even though inflammatory marker reductions were modest (234). A double-blind RCT investigating tVNS on human cognition after sleep deprivation showed that the active group performed significantly better on arousal, multi-tasking, and reported significantly lower fatigue ratings compared to sham (235). In an RCT of 247 women with breast cancer undergoing radiotherapy, daily tVNS was reported to significantly improve CRF 1 month post-treatment, while also improving depression scores and social functioning (236). Consistent with Yin et al. (236), we found that taVNS significantly reduced CRF after 2 weeks of use nightly use (15 min each session) prior to going to sleep (61).

VNS and breast cancer biology

Across disease domains, tVNS shows consistent benefits for insomnia and affective symptoms, with promising improvements in cognition, fatigue, and pain. These findings are promising, but remain heterogeneous, reflecting the large variety of tVNS methods and assays used across studies. There remain gaps in efficacy in cancer populations and co-measurements of symptom relief and biometric/inflammatory/autonomic markers. Cancer biology is complex, having several hundreds of different types and involving multiple body systems. Nevertheless, two crucial etiological factors in all cancers are genetic changes or instability and the immune inflammatory response, which contribute to all stages of tumorigenesis. Importantly, tumor initiation and progression are driven by three interrelated biological processes (1): oxidative stress that induces DNA damage (2); inflammatory signaling that supports apoptotic escape, angiogenesis, and metastatic potential; and (3) heightened sympathetic activation that shapes metastatic distribution and facilitates tumor proliferation (237). VNS has been shown to reduce oxidative stress and enhance antioxidant defense pathways (238), modulate innate and adaptive inflammatory signaling to help coordinate neuroimmune responses (239), profoundly inhibit inflammation (50), enhance cellular immunity (240), and promote a more effective anti-tumor immune environment (241). Therefore, tVNS may have a prognostic and protective role in cancer that is worth mentioning. The examples discussed in this section represent only a small subset of the emerging direction and promise of VNS in cancer medicine (50, 241, 242).

Discussion

The symptom clusters described above reflect a shared neuroimmune–autonomic dysregulation that converges on vagal withdrawal, tonic LC hyperarousal, HPA axis disruption, and persistent inflammatory amplification. As discussed, insomnia, anxiety, depression, pain, cognitive dysfunction, and CRF are sustained not by isolated etiologies, but by interacting psychophysiological loops anchored in central vagal pathways. Evidence described demonstrates that tVNS exerts clinically meaningful effects across these symptom domains. Together, this mechanistic and clinical overlap suggests that tVNS is not merely a symptom-alleviating tool, but a circuit-level intervention suited to treating breast cancer distress as a cluster-based syndrome (Table 1, Figure 2) rather than as a series of disconnected complaints.

Vagal stimulation offers a uniquely upstream therapeutic approach because it interfaces with multiple systems simultaneously that jointly govern autonomic balance, affective regulation, and anti-inflammatory modulation (Figures 1, 3). This aligns findings from studies showing cross-symptom improvements in sleep, mood, fatigue, and nociception following tVNS in clinical and preclinical trials. In this way, tVNS is conceptually positioned not as a niche or adjunctive therapy but as a promising bioelectronic intervention for targeting the architecture of breast cancer symptom

clustering (Table 1). Thus, a translational tVNS model for patients with breast cancer should move beyond single-symptom applications and toward cluster-stratified deployment, wherein individuals presenting with insomnia–fatigue–anxiety constellations, pain–cognitive fog networks, or depression–hyperarousal phenotypes are matched to vagally mediated intervention strategies targeting their dominant autonomic–inflammatory drivers (Figures 3, 4). This cluster-centric framing supports precision survivorship paradigms and sets the foundation for biomarker-based personalization strategies (Figure 4). However, to make biomarkers truly useful for guiding tVNS treatments in breast cancer, future studies should determine specific, measurable cutoff values that define different patient types. Once these quantitative thresholds are established, clinicians may use biomarker data to more confidently match patients with the most appropriate tVNS protocols.

To rigorously evaluate tVNS in breast cancer survivorship, future clinical trials should be designed to assess both symptom outcomes and mechanistic pathway engagement. Standard endpoints should include validated measures of sleep disturbance, fatigue, anxiety, depressive symptoms, pain interference, and cognitive function, ideally grouped by symptom clusters rather than isolated domains. Given the heterogeneity of psychophysiological burden across breast cancer survivorship, personalization of tVNS delivery may enhance clinical efficacy by aligning stimulation parameters with distinct autonomic and inflammatory phenotypes individualized to patients of varying or domains (Table 3 and Figure 4). Additional research is required to determine how specific tVNS methods and parameters affect different symptom outcomes across individuals to develop phenotypic response profiles and fully realize a precision-guided approach.

HRV provides a non-invasive marker of vagal tone and has been consistently associated with fatigue, insomnia, mood disturbance, and broader symptom clustering (37, 92). Individuals characterized by pronounced vagal withdrawal as determined by HRV may represent a high-yield target group for tVNS, particularly when addressing hyperarousal-related insomnia, anxiety, and cognitive inefficiency. As mentioned above, however, more research is needed to clearly establish these phenotypes and response profiles. Inflammatory profiling similarly also offers a pathway for guiding tVNS selection and monitoring. Elevated IL-6, TNF- α , and CRP levels have been linked to pain sensitization, CRF, depressive symptoms, and psychomotor slowing (72, 145). Patients exhibiting a high-cytokine phenotype may respond preferentially to CAIP-engaging tVNS protocols or to combination regimens that integrate anti-inflammatory lifestyle interventions (e.g., exercise, nutrition changes, or stress-reduction therapies). Dynamic cytokine tracking may also serve as a mechanistic engagement marker, enabling assessment and real-time titration of stimulation based on inflammatory reflex responsiveness.

Neurocognitive arousal profiling may further refine subgroup identification. Digital biomarkers such as pupillary dilation, polysomnography, EEG and other imaging, psychomotor vigilance task performance, or task-related HRV reactivity provide indirect yet scalable proxies of tonic vs. phasic LC firing and cognitive effort burden. When used alongside subjective

indicators such as perceived fatigue or mental load, these markers may support a precision neuromodulation classification framework and better therapeutic outcome. Parallel assessment of autonomic and inflammatory biomarkers, such as HRV, IL-6, TNF- α , CRP, cortisol slope, and pupillary reactivity, can help determine whether improvements are mediated through LC-HPA-CAIP recalibration, offering biological validation of the proposed mechanism-based survivorship model. Incorporating appropriate assessments, digital phenotyping of stress and fatigue load, and wearable HRV tracking may allow dynamic evaluation of within-person tVNS effects on diurnal regulation and reactivity to daily demands (Table 3, Figure 4).

The integration of autonomic, inflammatory, and arousal biomarkers is now being operationalized through next-generation bioelectronic medicine. Closed-loop tVNS systems leverage real-time physiological sensing (e.g., HRV, electrodermal activity, sleep state transitions, and pupillometry) to dynamically adjust stimulation parameters in accordance with autonomic or arousal fluctuations (106). By delivering stimulation during windows of vagal receptivity or sympathetic overdrive, these feedback-responsive systems optimize frequency, duration, timing, and modality (e.g., taVNS vs. tcVNS) to align with patient-specific psychophysiological states (Figure 4). Indeed, dose-response studies comparing stimulation frequency, duration, and timing relative to behavioral interventions are limited and will be essential in defining optimal parameters for specific symptom constellations. This biomarker-informed, adaptive dosing framework represents a shift from uniform stimulation protocols toward precision, phenotype-aligned bioelectronic interventions that enhance mechanistic engagement and improved therapeutic outcomes. By embedding mechanistic biomarkers, cluster-specific endpoints, and psychophysiological stratification strategies, clinical trials can accelerate the development of precision neuromodulation paradigms for survivorship care (Table 3, Figure 4).

Breast cancer survivorship is frequently marked by a constellation of psychophysiological symptoms that reflect a shared axis of autonomic dysregulation, inflammatory persistence, and central arousal imbalance. Non-invasive vagus nerve stimulation offers a circuit-level intervention uniquely positioned to target these symptom clusters through modulation of LC-HPA-CAIP pathways, restoration of parasympathetic tone, and attenuation of neuroimmune amplification. Evidence from diverse clinical populations supports its efficacy across individual symptom domains, and emerging feasibility data suggest its translational relevance for breast cancer survivors. By aligning tVNS delivery with psychophysiological phenotyping and integrating it into multimodal survivorship care models, this neuromodulatory approach may enhance the effectiveness of behavioral, rehabilitative, and anti-inflammatory interventions (Table 3, Figure 4). While direct evidence in breast cancer-specific populations remains in early development, the mechanistic coherence and cross-domain efficacy of tVNS support its advancement as a promising tool in neuroimmune-informed survivorship care. tVNS holds promise not only for symptom

alleviation but also for sustained autonomic resilience and immune homeostasis. As oncology continues to evolve toward biologically grounded, circuit-targeted intervention strategies, non-invasive vagal neuromodulation may play a pivotal role in shaping the future of personalized neuroimmune-based supportive cancer care.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

MD: Conceptualization, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing. WT: Conceptualization, Investigation, Project administration, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

WT is a co-founder of IST, LLC and an inventor and co-inventor on vagus nerve stimulation and other neuromodulation methods and devices for treating various disorders.

The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. The author(s) declare that Google Notebook LM was used to produce graphical approaches to generating concise illustrations for Figures 2-4. The authors declare no other Generative AI tools were used in the preparation of this manuscript. The authors claim all responsibility for the final draft of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer J Clin.* (2021) 71:209–49. doi: 10.3322/caac.21660
- So WKW, Law BMH, Ng MSN, He X, Chan DNS, Chan CWH, et al. Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review. *Cancer Med.* (2021) 10:2531–65. doi: 10.1002/cam4.3794
- Nguyen J, Cramarossa G, Bruner D, Chen E, Khan L, Leung A, et al. A literature review of symptom clusters in patients with breast cancer. *Expert Rev Pharmacoeconom Outcomes Res.* (2011) 11:533–9. doi: 10.1586/erp.11.55
- Fiorentino L, Rissling M, Liu L, Ancoli-Israel S. The symptom cluster of sleep, fatigue and depressive symptoms in breast cancer patients: severity of the problem and treatment options. *Drug Discov Today Dis Models.* (2011) 8:167–73. doi: 10.1016/j.ddmod.2011.05.001
- Bjerkset E, Röhrh K, Schou-Bredal I. Symptom cluster of pain, fatigue, and psychological distress in breast cancer survivors: prevalence and characteristics. *Breast Cancer Res Treat.* (2020) 180:63–71. doi: 10.1007/s10549-020-05522-8
- Hamer J, McDonald R, Zhang L, Verma S, Leahey A, Eccleston C, et al. Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. *Supportive Care Cancer.* (2017) 25:409–19. doi: 10.1007/s00520-016-3417-6
- Kissane DW, Grabsch B, Love A, Clarke DM, Bloch S, Smith GC. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. *Aust New Z J Psychiatry.* (2004) 38:320–6. doi: 10.1080/j.1440-1614.2004.01358.x
- Bultz BD. Patient care and outcomes: why cancer care should screen for distress, the 6th vital sign. *Asia-Pacific J Oncol Nurs.* (2016) 3:21–4. doi: 10.4103/2347-5625.178163
- Byar KL, Berger AM, Bakken SL, Cetak MA. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. *Oncol Nurs Forum.* (2006) 33:E18–26. doi: 10.1188/06.ONF.E18-E26
- McFarland DC, Shaffer KM, Tiersten A, Holland J. Physical symptom burden and its association with distress, anxiety, and depression in breast cancer. *Psychosomatics.* (2018) 59:464–71. doi: 10.1016/j.psym.2018.01.005
- Kenne Sarenmalm E, Browall M, Gaston-Johansson F. Symptom burden clusters: A challenge for targeted symptom management. A Longitudinal Study Examining Symptom Burden Clusters in Breast Cancer. *J Pain Symptom Manage.* (2014) 47:731–41. doi: 10.1016/j.jpainsymman.2013.05.012
- Kwak A, Jacobs J, Haggett D, Jimenez R, Peppercorn J. Evaluation and management of insomnia in women with breast cancer. *Breast Cancer Res Treat.* (2020) 181:269–77. doi: 10.1007/s10549-020-05635-0
- Kissane DW, Ildn J, Bloch S, Vitetta L, Clarke DM, Smith GC, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. *Med J Aust.* (1998) 169:192–6. doi: 10.5694/j.1326-5377.1998.tb140220.x
- Yu S, Li W, Tang L, Fan X, Yao S, Zhang X, et al. Depression in breast cancer patients: Immunopathogenesis and immunotherapy. *Cancer Lett.* (2022) 536:215648. doi: 10.1016/j.canlet.2022.215648
- Ahn SK, Oh S, Kim J, Choi JS, Hwang KT. Psychological impact of type of breast cancer surgery: A national cohort study. *World J Surg.* (2022) 46:2224–33. doi: 10.1007/s00268-022-06585-y
- Nakamura ZM, Deal AM, Nyrop KA, Chen YT, Quillen LJ, Brenizer T, et al. Serial assessment of depression and anxiety by patients and providers in women receiving chemotherapy for early breast cancer. *Oncol.* (2021) 26:147–56. doi: 10.1002/onco.13528
- Savard J, Simard S, Blanchet J, Ivers H, Morin CM. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. *Sleep.* (2001) 24:583–90. doi: 10.1093/sleep/24.5.583
- Irwin MR. Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. *Curr Psychiatry Rep.* (2013) 15:404. doi: 10.1007/s11920-013-0404-1
- Grayson S, Sereika S, Harpel C, Diego E, Steiman JG, McAuliffe PF, et al. Factors associated with sleep disturbances in women undergoing treatment for early-stage breast cancer. *Supportive Care Cancer.* (2022) 30:157–66. doi: 10.1007/s00520-021-06373-9
- Balachandran DD, Bashoura L, Sheshadri A, Manzullo E, Faiz SA. The impact of immunotherapy on sleep and circadian rhythms in patients with cancer. *Front Oncol.* (2023) 13:1295267. doi: 10.3389/fonc.2023.1295267
- Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. *New Engl J Med.* (2021) 385:395–405. doi: 10.1056/NEJMoa2104162
- Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. *Japanese J Clin Oncol.* (2020) 50:225–9. doi: 10.1093/jjco/hyzz213
- Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. *Biol Psychiatry.* (2003) 54:269–82. doi: 10.1016/S0006-3223(03)00566-3
- Ibrar M, Peddie N, Agnew S, Diserholt A, Fleming L. Breast cancer survivors' lived experience of adjuvant hormone therapy: A thematic analysis of medication side effects and their impact on adherence. *Front Psychol.* (2022) 13:861198. doi: 10.3389/fpsyg.2022.861198
- Sanft T, Day A, Ansbaugh S, Armenian S, Baker KS, Ballinger T, et al. NCCN guidelines® Insights: survivorship, version 1.2023. *J Natl Compr Cancer Network: JNCCN.* (2023) 21:792–803. doi: 10.6004/jnccn.2023.0041
- Mollica MA, McWhirter G, Tonorez E, Fenderson J, Freyer DR, Jefford M, et al. Developing national cancer survivorship standards to inform quality of care in the United States using a consensus approach. *J Cancer Survivorship.* (2024) 18:1190–9. doi: 10.1007/s11764-024-01602-6
- Jefford M, Nekhlyudov L, Smith AL, Chan RJ, Lai-Kwon J, Hart NH. Survivorship care for people affected by advanced or metastatic cancer: building on the recent multinational association of supportive care in cancer-ASCO standards and practice recommendations. *Am Soc Clin Oncol Educ Book.* (2025) 45:e471752. doi: 10.1200/EDBK-25-471752
- Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. *J Clin Oncol.* (2012) 30:3687–96. doi: 10.1200/JCO.2012.41.7238
- Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. *Sleep Med Rev.* (2006) 10:419–29. doi: 10.1016/j.smrv.2006.03.005
- Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med.* (2021) 17:255–62. doi: 10.5664/jcsm.8986
- Grassi L, Zachariae R, Caruso R, Palagini L, Campos-Ródenas R, Riba MB, et al. Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline. *ESMO Open.* (2023) 8:102047. doi: 10.1016/j.esmoop.2023.102047
- Fernandez E, Salem D, Swift JK, Ramtahal N. Meta-analysis of dropout from cognitive behavioral therapy: Magnitude, timing, and moderators. *J Consult Clin Psychol.* (2015) 83:1108–22. doi: 10.1037/ccp0000044
- McClure JM, Merk FL, Anderson J, Aggarwal A, Stark LJ. Expanding access to cognitive behavioral therapy: A purposeful and effective model for integration. *Cogn Behav Pract.* (2024) 31:286–98. doi: 10.1016/j.cbpra.2023.09.005
- Geraldes V, Caldeira E, Afonso A, MaChado F, Amaro-Leal Â, Laranjo S, et al. Cardiovascular dysautonomia in patients with breast cancer. *Open Cardiovasc Med J.* (2022) 16:e187419242206271. doi: 10.2174/18741924-v16-e2206271
- Fagundes CP, Murray DM, Hwang BS, Gouin J-P, Thayer JF, Sollers JJ, et al. Sympathetic and parasympathetic activity in cancer-related fatigue: More evidence for a physiological substrate in cancer survivors. *Psychoneuroendocrinology.* (2011) 36:1137–47. doi: 10.1016/j.psyneuen.2011.02.005
- Huber A, Koenig J, Bruns B, Bendszus M, Friederich H-C, Simon JJ. Brain activation and heart rate variability as markers of autonomic function under stress. *Sci Rep.* (2025) 15:28114. doi: 10.1038/s41598-025-12430-8
- Giese-Davis J, Wilhelm FH, Tamagawa R, Palesh O, Neri E, Taylor CB, et al. Higher vagal activity as related to survival in patients with advanced breast cancer: an analysis of autonomic dysregulation. *Psychosom Med.* (2015) 77:346–55. doi: 10.1097/PSY.0000000000000167
- Zhou X, Ma Z, Zhang L, Zhou S, Wang J, Wang B, et al. Heart rate variability in the prediction of survival in patients with cancer: A systematic review and meta-analysis. *J Psychosom Res.* (2016) 89:20–5. doi: 10.1016/j.jpsychores.2016.08.004
- Ricon-Becker I, Fogel E, Cole SW, Haldar R, Lev-Ari S, Gidron Y. Tone it down: Vagal nerve activity is associated with pro-inflammatory and anti-viral factors in breast cancer – An exploratory study. *Compr Psychoneuroendocrinol.* (2021) 7:100057. doi: 10.1016/j.cpnec.2021.100057
- Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: Adaptive Gain and Optimal Performance. *Annu Rev Neurosci.* (2005) 28:403–50. doi: 10.1146/annurev.neuro.28.061604.135709

41. Collins L, Boddington L, Steffan PJ, McCormick D. Vagus nerve stimulation induces widespread cortical and behavioral activation. *Curr Biol*. (2021) 31:2088–2098.e3. doi: 10.1016/j.cub.2021.02.049
42. Koopman FA, Chavan SS, Mijlko S, Grazio S, Sokolovic S, Schuurman PR, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. *Proc Natl Acad Sci*. (2016) 113:8284–9. doi: 10.1073/pnas.1605635113
43. Ding L, Yang Y, Chi M, Chen Z, Huang Y, Ouyang W, et al. Diagnostic role of heart rate variability in breast cancer and its relationship with peripheral serum carcinoembryonic antigen. *PLoS One*. (2023) 18:e0282221. doi: 10.1371/journal.pone.0282221
44. Huang W-B, H-z L, Long J, Ma Q, Fu X, You F-M, et al. Vagal nerve activity and cancer prognosis: a systematic review and meta-analysis. *BMC Cancer*. (2025) 25:579. doi: 10.1186/s12885-025-13956-w
45. Badran BW, Austelle CW. The future is noninvasive: A brief review of the evolution and clinical utility of vagus nerve stimulation. *Focus (American Psychiatr Publishing)*. (2022) 20:3–7. doi: 10.1176/appi.focus.20210023
46. Elmati PR, Abd-Elsayed A, Staats PS, Bautista A. Noninvasive vagus nerve stimulation: History, mechanisms, indications, and obstacles. In: *Vagus nerve stimulation*. Cambridge, MA, USA: Elsevier (2025). p. 69–81.
47. Afra P, Adamolekun B, Aydemir S, Watson GDR. Evolution of the vagus nerve stimulation (VNS) therapy system technology for drug-resistant epilepsy. *Front Med Technol*. (2021) 3:696543. doi: 10.3389/fmedt.2021.696543
48. Wang L, Wang Y, Wang Y, Wang F, Zhang J, Li S, et al. Transcutaneous auricular vagus nerve stimulators: a review of past, present, and future devices. *Expert Rev Med Dev*. (2022) 19:43–61. doi: 10.1080/17434440.2022.2020095
49. Redgrave J, Day D, Leung H, Laud PJ, Ali A, Lindert R, et al. Safety and tolerability of Transcutaneous Vagus Nerve stimulation in humans; a systematic review. *Brain Stimulation*. (2018) 11:1225–38. doi: 10.1016/j.brs.2018.08.010
50. Abdullahi A, Wong TWL, Ng SSM. Putative role of non-invasive vagus nerve stimulation in cancer pathology and immunotherapy: Can this be a hidden treasure, especially for the elderly? *Cancer Med*. (2023) 12:19081–90. doi: 10.1002/cam4.6466
51. Yap JY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical review of transcutaneous vagus nerve stimulation: challenges for translation to clinical practice. *Front Neurosci*. (2020) 14:284. doi: 10.3389/fnins.2020.00284
52. Austelle CW, O'Leary GH, Thompson S, Gruber E, Kahn A, Manett AJ, et al. A comprehensive review of vagus nerve stimulation for depression. *NeuroModul: Technol at Neural Interface*. (2022) 25:309–15. doi: 10.1111/ner.13528
53. Magoun HW. An ascending reticular activating system in the brain stem. *Arch Neurol And Psychiatry*. (1952) 67:145. doi: 10.1001/archneurpsyc.1952.02320140013002
54. Urbin MA, Lefe CW, Simpson TW, Wittenberg GF, Chandrasekaran B, Weber DJ. Electrical stimulation of the external ear acutely activates noradrenergic mechanisms in humans. *Brain Stimulation*. (2021) 14:990–1001. doi: 10.1016/j.brs.2021.06.002
55. Chae J-H, Nahas Z, Lomarev M, Denslow S, Lorberbaum JP, Bohning DE, et al. A review of functional neuroimaging studies of vagus nerve stimulation (VNS). *J Psychiatr Res*. (2003) 37:443–55. doi: 10.1016/S0022-3956(03)00074-8
56. Cao J, Lu K-H, Powley TL, Liu Z. Vagal nerve stimulation triggers widespread responses and alters large-scale functional connectivity in the rat brain. *PLoS One*. (2017) 12:e0189518. doi: 10.1371/journal.pone.0189518
57. Kim H, Jung HR, Kim JB, Kim D-J. Autonomic dysfunction in sleep disorders: from neurobiological basis to potential therapeutic approaches. *J Clin Neurol*. (2022) 18:140. doi: 10.3988/jcn.2022.18.2.140
58. Frangos E, Ellrich J, Komisaruk BR. Non-invasive Access to the Vagus Nerve Central Projections via Electrical Stimulation of the External Ear: fMRI Evidence in Humans. *Brain Stimulation*. (2015) 8:624–36. doi: 10.1016/j.brs.2014.11.018
59. Clancy JA, Mary DA, Witte KK, Greenwood JP, Deuchars SA, Deuchars J. Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. *Brain Stimulation*. (2014) 7:871–7. doi: 10.1016/j.brs.2014.07.031
60. Yuan H, Silberstein SD. Vagus nerve and vagus nerve stimulation, a comprehensive review: part I. *Headache: J Head Face Pain*. (2016) 56:71–8. doi: 10.1111/head.12647
61. Do M, Evancho A, Tyler WJ. Bilateral transcutaneous auricular vagus nerve stimulation for the treatment of insomnia in breast cancer. *Sci Rep*. (2025) 61. doi: 10.1038/s41598-025-30600-6
62. Austelle CW, Cox SS, Wills KE, Badran BW. Vagus nerve stimulation (VNS): recent advances and future directions. *Clin Autonomic Res*. (2024) 34:529–47. doi: 10.1007/s10286-024-01065-w
63. Ho S-Y, Rohan KJ, Parent J, Tager FA, McKinley PS. A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. *J Pain Symptom Manage*. (2015) 49:707–15. doi: 10.1016/j.jpainsymman.2014.09.009
64. Kim H-J, Barsevick AM, Tulman L, McDermott PA. Treatment-related symptom clusters in breast cancer: A secondary analysis. *J Pain Symptom Manage*. (2008) 36:468–79. doi: 10.1016/j.jpainsymman.2007.11.011
65. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol Nurs Forum*. (2001) 28:465–70.
66. Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters on functional status and quality of life in women with breast cancer. *Eur J Oncol Nurs*. (2010) 14:101–10. doi: 10.1016/j.ejon.2009.09.005
67. Hsiao C-P, Von Ah D, Chen M-K, Saligan LN. Relationship of cancer-related fatigue with psychoneurophysiological (PNP) symptoms in breast cancer survivors. *Eur J Oncol Nurs*. (2024) 68:102469. doi: 10.1016/j.ejon.2023.102469
68. Berger AM, Visovsky C, Hertzog M, Holtz S, Loberiza FR. Usual and worst symptom severity and interference with function in breast cancer survivors. *J Supportive Oncol*. (2012) 10:112–8. doi: 10.1016/j.suonc.2011.11.001
69. Ebbestad FE, Ammitzbøll G, Horsbøll TA, Andersen I, Johansen C, Zehran B, et al. The long-term burden of a symptom cluster and association with longitudinal physical and emotional functioning in breast cancer survivors. *Acta Oncol*. (2023) 62:706–13. doi: 10.1080/0284186X.2023.2185909
70. Agnew S, Crawford M, MacPherson I, Shiramizu V, Fleming L. The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. *Breast (Edinburgh Scotland)*. (2024) 75:103731. doi: 10.1016/j.breast.2024.103731
71. Miaskowski C, Barsevick A, Berger A, Casagrande R, Grady PA, Jacobsen P, et al. Advancing symptom science through symptom cluster research: expert panel proceedings and recommendations. *J Natl Cancer Inst*. (2017) 109:djw253. doi: 10.1093/jnci/djw253
72. Bower JE. The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms. *Cancer*. (2019) 125:353–64. doi: 10.1002/cncr.31790
73. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. *Nat Rev Clin Oncol*. (2014) 11:597–609. doi: 10.1038/nrclinonc.2014.127
74. Potosky AL, Graves KD, Lin L, Pan W, Fall-Dickson JM, Ahn J, et al. The prevalence and risk of symptom and function clusters in colorectal cancer survivors. *J Cancer Survivorship: Res Pract*. (2022) 16:1449–60. doi: 10.1007/s11764-021-01123-6
75. Lynch Kelly D, Dickinson K, Hsiao C-P, Lukkahatai N, Gonzalez-Marrero V, McCabe M, et al. Biological basis for the clustering of symptoms. *Semin Oncol Nurs*. (2016) 32:351–60. doi: 10.1016/j.soncn.2016.08.002
76. Tong H-H, Li J-R, Feng Y, Li S-W, Qiu H, Hong J-F. The association between sleep disturbance and proinflammatory markers in patients with cancer: A meta-analysis. *Cancer Nurs*. (2023) 46:E91–8. doi: 10.1097/NCC.0000000000001055
77. Zhang Y, Tan X, Tang C. Estrogen-immuno-neuromodulation disorders in menopausal depression. *J Neuroinflamm*. (2024) 21:159. doi: 10.1186/s12974-024-03152-1
78. Lee B-N, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. *Neuroimmunomodul*. (2004) 11:279–92. doi: 10.1159/000079408
79. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?: A cytokine-immunologic model of cancer symptoms. *Cancer*. (2003) 97:2919–25. doi: 10.1002/cncr.11382
80. Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. *Biol Psychiatry*. (2016) 80:40–52. doi: 10.1016/j.biopsych.2015.05.014
81. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. *J Clin Oncol*. (2008) 26:971–82. doi: 10.1200/JCO.2007.10.7805
82. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. (2008) 454:436–44. doi: 10.1038/nature07205
83. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell*. (2010) 140:883–99. doi: 10.1016/j.cell.2010.01.025
84. Hajj A, Chamoun R, Salameh P, Khoury R, Hachem R, Sacre H, et al. Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors. *BMC Cancer*. (2022) 22:16. doi: 10.1186/s12885-021-09072-0
85. Janelins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. *J Clin Oncol*. (2017) 35:506–14. doi: 10.1200/JCO.2016.68.5826
86. Tracey KJ. The inflammatory reflex. *Nature*. (2002) 420:853–9. doi: 10.1038/nature01321
87. Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. *Am Heart J*. (2015) 170:231–41. doi: 10.1016/j.ahj.2015.05.014
88. Qin J-F, Jin F-J, Li N, Guan H-T, Lan L, Ni H, et al. Adrenergic receptor β_2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. *BMB Rep*. (2015) 48:295–300. doi: 10.5483/bmbrep.2015.48.5.008
89. Crosswell AD, Lockwood KG, Ganz PA, Bower JE. Low heart rate variability and cancer-related fatigue in breast cancer survivors. *Psychoneuroendocrinology*. (2014) 45:58–66. doi: 10.1016/j.psyneuen.2014.03.011

90. Kloter E, Barrueto K, Klein SD, Scholkmann F, Wolf U. Heart rate variability as a prognostic factor for cancer survival – A systematic review. *Front Physiol.* (2018) 9:623. doi: 10.3389/fphys.2018.00623
91. Caro-Morán E, Fernández-Lao C, Galiano-Castillo N, Cantarero-Villanueva I, Arroyo-Morales M, Díaz-Rodríguez L. Heart rate variability in breast cancer survivors after the first year of treatments: A case-controlled study. *Biol Res For Nurs.* (2016) 18:43–9. doi: 10.1177/1099800414568100
92. Arab C, Dias DPM, Barbosa RTDA, Carvalho TDD, Valenti VE, Crocetta TB, et al. Heart rate variability measure in breast cancer patients and survivors: A systematic review. *Psychoneuroendocrinology.* (2016) 68:57–68. doi: 10.1016/j.psyneuen.2016.02.018
93. Karvinen KH, Murray NP, Arastu H, Allison RR. Stress reactivity, health behaviors, and compliance to medical care in breast cancer survivors. *Oncol Nurs Forum.* (2013) 40:149–56. doi: 10.1188/13.ONF.149-156
94. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. *Nat Rev Immunol.* (2011) 11:625–32. doi: 10.1038/nri3042
95. Cooper TM, McKinley PS, Seeman TE, Choo T-H, Lee S, Sloan RP. Heart rate variability predicts levels of inflammatory markers: Evidence for the vagal anti-inflammatory pathway. *Brain Behav Immun.* (2015) 49:94–100. doi: 10.1016/j.bbi.2014.12.017
96. Adam J, Rupprecht S, Künstler ECS, Hoyer D. Heart rate variability as a marker and predictor of inflammation, nosocomial infection, and sepsis – A systematic review. *Autonomic Neurosci.* (2023) 249:103116. doi: 10.1016/j.autneu.2023.103116
97. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. *Mol Med.* (2007) 13:178–84. doi: 10.2119/2006-00112.Sloan
98. Chen X, Wang M, Yu K, Xu S, Qiu P, Lyu Z, et al. Chronic stress-induced immune dysregulation in breast cancer: Implications of psychosocial factors. *J Translational Med.* (2023) 11:226–33. doi: 10.2478/jtm-2021-0050
99. Desai K, Mao JJ, Su I, DeMichele A, Li Q, Xie SX, et al. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors. *Supportive Care Cancer.* (2013) 21:43–51. doi: 10.1007/s00520-012-1490-z
100. Bower JE, Radin A, Ganz PA, Irwin MR, Cole SW, Petersen L, et al. Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination. *Cancer.* (2025) 131:e70038. doi: 10.1002/cncr.70038
101. Reddick BK, Nanda JP, Campbell L, Ryman DG, Gaston-Johansson F. Examining the influence of coping with pain on depression, anxiety, and fatigue among women with breast cancer. *J Psychosocial Oncol.* (2005) 23:137–57. doi: 10.1300/J077v23n02_09
102. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. *Dialogues Clin Neurosci.* (2008) 10:473–81. doi: 10.31887/DCNS.2008.10.4/plfranzen
103. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young Adults. *Biol Psychiatry.* (1996) 39:411–8. doi: 10.1016/0006-3223(95)00188-3
104. Badran BW, Mithoefer OJ, Summer CE, LaBate NT, Glusman CE, Badran AW, et al. Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate. *Brain Stimulation.* (2018) 11:699–708. doi: 10.1016/j.brs.2018.04.004
105. Hilz MJ. Transcutaneous vagus nerve stimulation - A brief introduction and overview. *Autonomic Neurosci.* (2022) 243:103038. doi: 10.1016/j.autneu.2022.103038
106. Tyler WJ. Auricular bioelectronic devices for health, medicine, and human-computer interfaces. *Front Electron.* (2025) 6:1503425. doi: 10.3389/felec.2025.1503425
107. Nissen ER, Neumann H, Knutzen SM, Henriksen EN, Amidi A, Johansen C, et al. Interventions for insomnia in cancer patients and survivors—a comprehensive systematic review and meta-analysis. *JNCI Cancer Spectr.* (2024) 8:pkae041. doi: 10.1093/jncics/pkae041
108. Davidson JR, MacLean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. *Soc Sci Med.* (2002) 54:1309–21. doi: 10.1016/S0277-9536(01)00043-0
109. Lockefeer JPM, De Vries J. What is the relationship between trait anxiety and depressive symptoms, fatigue, and low sleep quality following breast cancer surgery? *Psycho-Oncology.* (2013) 22:1127–33. doi: 10.1002/pon.3115
110. Palesh O, Aldridge-Gerry A, Ulusakarya A, Ortiz-Tudela E, Capuron L, Innominato PF. Sleep disruption in breast cancer patients and survivors. *J Natl Compr Cancer Network.* (2013) 11:1523–30. doi: 10.6004/jnccn.2013.0179
111. Palesh O, Aldridge-Gerry A, Zeitzer JM, Koopman C, Neri E, Giese-Davis J, et al. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. *Sleep.* (2014) 37:3837–42. doi: 10.5665/sleep.3642
112. Koopman C, Nouriani B, Erickson V, Anupindi R, Butler LD, Bachmann MH, et al. Sleep disturbances in women with metastatic breast cancer. *Breast J.* (2002) 8:362–70. doi: 10.1046/j.1524-4741.2002.08606.x
113. Fortner BV, Stepanski EJ, Wang SC, Kasprovicz S, Durrence HH. Sleep and quality of life in breast cancer patients. *J Pain Symptom Manage.* (2002) 24:471–80. doi: 10.1016/S0885-3924(02)00500-6
114. Ratcliff CG, Zepeda SG, Hall MH, Tullus EA, Fowler S, Chaoul A, et al. Patient characteristics associated with sleep disturbance in breast cancer survivors. *Supportive Care Cancer.* (2021) 29:2601–11. doi: 10.1007/s00520-020-05777-3
115. Dzierzewski JM, Donovan EK, Kay DB, Sannes TS, Bradbrook KE. Sleep inconsistency and markers of inflammation. *Front Neurol.* (2020) 11:1042. doi: 10.3389/fneur.2020.01042
116. Irwin MR, Olmstead R, Bjurstrom MF, Finan PH, Smith MT. Sleep disruption and activation of cellular inflammation mediate heightened pain sensitivity: a randomized clinical trial. *Pain.* (2023) 164:1128–37. doi: 10.1097/j.pain.0000000000002811
117. Irwin MR, Opp MR. Sleep health: reciprocal regulation of sleep and innate immunity. *Neuropsychopharmacology.* (2017) 42:129–55. doi: 10.1038/npp.2016.148
118. Krueger JM. The role of cytokines in sleep regulation. *Curr Pharm Des.* (2008) 14:3408–16. doi: 10.2174/138161208786549281
119. Bonnet MH, Arand DL. Hyperarousal and insomnia: State of the science. *Sleep Med Rev.* (2010) 14:9–15. doi: 10.1016/j.smrv.2009.05.002
120. Miglis MG. Autonomic dysfunction in primary sleep disorders. *Sleep Med.* (2016) 19:40–9. doi: 10.1016/j.sleep.2015.10.001
121. Bassi A, Bozzali M. Potential interactions between the autonomic nervous system and higher level functions in neurological and neuropsychiatric conditions. *Front Neurol.* (2015) 6:182. doi: 10.3389/fneur.2015.00182
122. Zoccoli G, Amici R. Sleep and autonomic nervous system. *Curr Opin Physiol.* (2020) 15:128–33. doi: 10.1016/j.cophys.2020.01.002
123. Chen P-C, Zhang J, Thayer JF, Mednick SC. Understanding the roles of central and autonomic activity during sleep in the improvement of working memory and episodic memory. *Proc Natl Acad Sci.* (2022) 119:e2123417119. doi: 10.1073/pnas.2123417119
124. Riemann D, Spiegelhalter K, Feige B, Voderholzer U, Berger M, Perlis M, et al. The hyperarousal model of insomnia: A review of the concept and its evidence. *Sleep Med Rev.* (2010) 14:19–31. doi: 10.1016/j.smrv.2009.04.002
125. Substance A, Mental Health Services A. *Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health.* Cambridge, MA, USA: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration (2022).
126. Krebber AMH, Buffart LM, Kleijn G, Riepma IC, De Bree R, Leemans CR, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. *Psycho-Oncology.* (2014) 23:121–30. doi: 10.1002/pon.3409
127. Tsaras K, Papatheasiou IV, Mitsi D, Veneti A, Kelesi M, Zyga S, et al. Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors. *Asian Pacific J Cancer Prevent: APJCP.* (2018) 19:1661–9. doi: 10.22034/APJCP.2018.19.6.1661
128. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. *J Clin Oncol.* (2008) 26:768–77. doi: 10.1200/JCO.2007.14.3248
129. Choi HL, Jeong SM, Jeon KH, Kim B, Jung W, Jeong A, et al. Depression risk among breast cancer survivors: a nationwide cohort study in South Korea. *Breast Cancer Res.* (2024) 26:188. doi: 10.1186/s13058-024-01948-w
130. Javan Biparva A, Raoofi S, Rafiei S, Masoumi M, Doustmehraban M, Bagheribayati F, et al. Global depression in breast cancer patients: Systematic review and meta-analysis. *PLoS One.* (2023) 18:e0287372. doi: 10.1371/journal.pone.0287372
131. Hessami A, Ghadirzadeh E, Ashrafi S, Taghavi F, Elyasi F, Gheibi M, et al. Depression, anxiety, and stress in breast cancer patients: prevalence, associated risk factors, and clinical correlates. *Sci Rep.* (2025) 15:31084. doi: 10.1038/s41598-025-17285-7
132. Reich M, Lesur A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. *Breast Cancer Res Treat.* (2008) 110:9–17. doi: 10.1007/s10549-007-9706-5
133. Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, et al. Depression and stress reactivity in metastatic breast cancer. *Psychosom Med.* (2006) 68:675–83. doi: 10.1097/01.psy.0000238216.88515.e5
134. Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. *Mol Psychiatry.* (2020) 25:3186–97. doi: 10.1038/s41380-020-00865-6
135. Watson M, Haviland J, Greer S, Davidson J, Bliss J. Influence of psychological response on survival in breast cancer: a population-based cohort study. *Lancet.* (1999) 354:1331–6. doi: 10.1016/S0140-6736(98)11392-2
136. Lei F, Vanderpool RC, McLouth LE, Romond EH, Chen Q, Durbin EB, et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. *Cancer.* (2023) 129:1821–35. doi: 10.1002/cncr.34676
137. Kanter NG, Cohen-Woods S, Balfour DA, Burt MG, Waterman AL, Koczwara B. Hypothalamic-pituitary-adrenal axis dysfunction in people with cancer: A systematic review. *Cancer Med.* (2024) 13:e70366. doi: 10.1002/cam4.70366
138. Ahmad MH, Rizvi MA, Fatima M, Mondal AC. Pathophysiological implications of neuroinflammation mediated HPA axis dysregulation in the prognosis of cancer and depression. *Mol Cell Endocrinol.* (2021) 520:111093. doi: 10.1016/j.mce.2020.111093
139. Gosain R, Gage-Bouchard E, Ambrosone C, Repasky E, Gandhi S. Stress reduction strategies in breast cancer: review of pharmacologic and non-

- pharmacologic based strategies. *Semin Immunopathol.* (2020) 42:719–34. doi: 10.1007/s00281-020-00815-y
140. Mather M, Thayer J. How heart rate variability affects emotion regulation brain networks. *Curr Opin Behav Sci.* (2018) 19:98–104. doi: 10.1016/j.cobeha.2017.12.017
141. Thayer JF, Lane RD. A model of neurovisceral integration in emotion regulation and dysregulation. *J Affect Disord.* (2000) 61:201–16. doi: 10.1016/S0165-0327(00)00338-4
142. Bonaz B, Sinniger V, Pellissier S. The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. *Front Immunol.* (2017) 8:1452. doi: 10.3389/fimmu.2017.01452
143. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex—linking immunity and metabolism. *Nat Rev Endocrinol.* (2012) 8:743–54. doi: 10.1038/nrendo.2012.189
144. Sălcudean A, Bodo C-R, Popovici R-A, Cozma M-M, Păcurar M, Crăciun R-E, et al. Neuroinflammation-A crucial factor in the pathophysiology of depression-A comprehensive review. *Biomolecules.* (2025) 15:502. doi: 10.3390/biom15040502
145. Ruiz-Casado A, Álvarez-Bustos A, De Pedro CG, Méndez-Otero M, Romero-Elias M. Cancer-related fatigue in breast cancer survivors: A review. *Clin Breast Cancer.* (2021) 21:10–25. doi: 10.1016/j.clbc.2020.07.011
146. Ji R-R, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. *Anesthesiology.* (2018) 129:343–66. doi: 10.1097/ALN.0000000000002130
147. Koenig J, Jarczok MN, Ellis RJ, Hillecke TK, Thayer JF. Heart rate variability and experimentally induced pain in healthy adults: A systematic review. *Eur J Pain.* (2014) 18:301–14. doi: 10.1002/ej.1532-2149.2013.00379.x
148. O'Rourke MA, Stokes S, Regina F, Susko K, Hendry W, Anderson A, et al. Heart rate variability (HRV) training for symptom control in cancer survivors. *J Clin Oncol.* (2017) 35:148–8. doi: 10.1200/JCO.2017.35.5_suppl.148
149. Forte G, Favieri F, Leemhuis E, De Martino ML, Giannini AM, De Gennaro L, et al. Ear your heart: transcutaneous auricular vagus nerve stimulation on heart rate variability in healthy young participants. *PeerJ.* (2022) 10:e14447. doi: 10.7717/peerj.14447
150. Spada GE, Masiero M, Pizzoli SFM, Pravettoni G. Heart rate variability biofeedback in cancer patients: A scoping review. *Behav Sci.* (2022) 12(10). doi: 10.3390/bs12100389
151. Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, et al. Cancer-related fatigue, version 2.2015. *J Natl Compr Cancer Network.* (2015) 13:1012–39. doi: 10.6004/jnccn.2015.0122
152. Palagini L, Miniati M, Riemann D, Zerbinati L. Insomnia, fatigue, and depression: theoretical and clinical implications of a self-reinforcing feedback loop in cancer. *Clin Pract Epidemiol Ment Health.* (2021) 17:257–63. doi: 10.2174/1745017902117010257
153. Tyler WJ, Boasso AM, Mortimore HM, Silva RS, Charlesworth JD, Marlin MA, et al. Transdermal neuromodulation of noradrenergic activity suppresses psychophysiological and biochemical stress responses in humans. *Sci Rep.* (2015) 5:13865. doi: 10.1038/srep13865
154. Liu C-H, Yang M-H, Zhang G-Z, Wang X-X, Li B, Li M, et al. Neural networks and the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation in depression. *J Neuroinflamm.* (2020) 17:54. doi: 10.1186/s12974-020-01732-5
155. Verma N, Mudge JD, Kasole M, Chen RC, Blanz SL, Trevathan JK, et al. Auricular vagus neuromodulation—A systematic review on quality of evidence and clinical effects. *Front Neurosci.* (2021) 15:664740. doi: 10.3389/fnins.2021.664740
156. Peuker ET, Filler TJ. The nerve supply of the human auricle. *Clin Anat.* (2002) 15:35–7. doi: 10.1002/ca.1089
157. Rong P, Liu J, Wang L, Liu R, Fang J, Zhao J, et al. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study. *J Affect Disord.* (2016) 195:172–9. doi: 10.1016/j.jad.2016.02.031
158. Stefan H, Kreiselmeyer G, Kerling F, Kurzbuch K, Rauch C, Heers M, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: A proof of concept trial. *Epilepsia.* (2012) 53:e115-e118. doi: 10.1111/j.1528-1167.2012.03492.x
159. Grazzi L, Usai S, Bussone G, EHMTI-0036. Gammacore device for treatment of migraine attack: preliminary report. *J Headache Pain.* (2014) 15:G12–1129-2377-15-S1-G12. doi: 10.1186/1129-2377-15-S1-G12
160. Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. *Epilepsy Res.* (1995) 22:53–62. doi: 10.1016/0920-1211(95)00035-9
161. Hulsey DR, Riley JR, Loerwald KW, Rennaker RL, Kilgard MP, Hays SA. Parametric characterization of neural activity in the locus coeruleus in response to vagus nerve stimulation. *Exp Neurol.* (2017) 289:21–30. doi: 10.1016/j.expneurol.2016.12.005
162. Van Egroo M, Koshmanova E, Vandewalle G, Jacobs HIL. Importance of the locus coeruleus-norepinephrine system in sleep-wake regulation: Implications for aging and Alzheimer's disease. *Sleep Med Rev.* (2022) 62:101592. doi: 10.1016/j.smrv.2022.101592
163. Aston-Jones G, Rajkowski J, Cohen J. Role of locus coeruleus in attention and behavioral flexibility. *Biol Psychiatry.* (1999) 46:1309–20. doi: 10.1016/S0006-3223(99)00140-7
164. Carter ME, Yizhar O, Chikahisa S, Nguyen H, Adamantidis A, Nishino S, et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. *Nat Neurosci.* (2010) 13:1526–33. doi: 10.1038/nn.2682
165. Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation: Neurographic correlates of induced eeg synchronization and desynchronization. *Brain Res.* (1967) 5:236–49. doi: 10.1016/0006-8993(67)90089-3
166. Chase MH, Nakamura Y. EEG response to afferent abdominal vagal stimulation. *Electroencephalog Clin Neurophysiol.* (1968) 24:396.
167. Dobrakowski P, Blaszkiewicz M, Skalski S. Changes in the electrical activity of the brain in the alpha and theta bands during prayer and meditation. *Int J Environ Res Public Health.* (2020) 17:9567. doi: 10.3390/ijerph17249567
168. Gurel NZ, Wittbrodt MT, Jung H, Shandhi MMH, Driggers EG, Ladd SL, et al. Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in posttraumatic stress disorder: A double-blind, randomized, sham controlled trial. *Neurobiol Stress.* (2020) 13:100264. doi: 10.1016/j.ynstr.2020.100264
169. Moazzami K, Pearce BD, Gurel NZ, Wittbrodt MT, Levantsevych OM, Huang M, et al. Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial. *J Affect Disord.* (2023) 342:85–90. doi: 10.1016/j.jad.2023.09.015
170. Sommer A, Fischer R, Borges U, Laborde S, Achtnetz S, Liepelt R. The effect of transcutaneous auricular vagus nerve stimulation (taVNS) on cognitive control in multitasking. *Neuropsychologia.* (2023) 187:108614. doi: 10.1016/j.neuropsychologia.2023.108614
171. Trifilio E, Shortell D, Olshan S, O'Neal A, Coyne J, Lamb D, et al. Impact of transcutaneous vagus nerve stimulation on healthy cognitive and brain aging. *Front Neurosci.* (2023) 17:1184051. doi: 10.3389/fnins.2023.1184051
172. Szeska C, Klepzig K, Hamm AO, Weymar M. Ready for translation: non-invasive auricular vagus nerve stimulation inhibits psychophysiological indices of stimulus-specific fear and facilitates responding to repeated exposure in phobic individuals. *Trans Psychiatry.* (2025) 15:135. doi: 10.1038/s41398-025-03352-0
173. Billman GE. Heart rate variability? A historical perspective. *Front Physiol.* (2011) 2011:86. doi: 10.3389/fphys.2011.00086
174. Reyes Del Paso GA, Langewitz W, Mulder LJM, Van Roon A, Duschek S. The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: A review with emphasis on a reanalysis of previous studies. *Psychophysiology.* (2013) 50:477–87. doi: 10.1111/psyp.12027
175. Goldstein DS, Benth O, Park M-Y, Sharabi Y. Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes: Low-frequency power of heart rate variability. *Exp Physiol.* (2011) 96:1255–61. doi: 10.1113/expphysiol.2010.056259
176. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. *Curr Neuropharmacol.* (2008) 6:235–53. doi: 10.2174/157015908785777229
177. Tyler WJ, Wyckoff S, Hearn T, Hool N. The safety and efficacy of transdermal auricular vagal nerve stimulation earbud electrodes for modulating autonomic arousal, attention, sensory gating, and cortical brain plasticity in humans. (2019) *bioRxiv.* 732529. doi: 10.1101/732529
178. Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. *J Cell Mol Med.* (2019) 23:2324–32. doi: 10.1111/jcmm.14170
179. Fagundes CP, Brown RL, Chen MA, Murdock KW, Saucedo L, LeRoy A, et al. Grief, depressive symptoms, and inflammation in the socially bereaved. *Psychoneuroendocrinology.* (2019) 100:190–7. doi: 10.1016/j.psyneuen.2018.10.006
180. Buckley TM, Schatzberg AF. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. *J Clin Endocrinol Metab.* (2005) 90:3106–14. doi: 10.1210/jc.2004-1056
181. Li S, Wang Y, Gao G, Guo X, Zhang Y, Zhang Z, et al. Transcutaneous auricular vagus nerve stimulation at 20 hz improves depression-like behaviors and down-regulates the hyperactivity of HPA axis in chronic unpredictable mild stress model rats. *Front Neurosci.* (2020) 2020:680. doi: 10.3389/fnins.2020.00680
182. Cuberos Paredes E, Goyes D, Mak S, Yardimian R, Ortiz N, McLaren A, et al. Transcutaneous auricular vagus nerve stimulation inhibits mental stress-induced cortisol release—Potential implications for inflammatory conditions. *Physiol Rep.* (2025) 13:e70251. doi: 10.14814/phy2.70251
183. Huynh R, Wong J, Cerami K, Viegas A, Chen M, Kania A, et al. Transcutaneous auricular vagus nerve stimulation may elicit anti-inflammatory actions through activation of the hypothalamic-pituitary-adrenal axis in humans. *Physiology.* (2023) 38:5734481. doi: 10.1152/physiol.2023.38.S1.5734481
184. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. *Viral Immunol.* (2005) 18:41–78. doi: 10.1089/vim.2005.18.41
185. Conway CR, Xiong W. The mechanism of action of vagus nerve stimulation in treatment-resistant depression. *Psychiatr Clinics North America.* (2018) 41:395–407. doi: 10.1016/j.psc.2018.04.005

186. Howells FM, Stein DJ, Russell VA. Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional performance. *Metab Brain Dis.* (2012) 27:267–74. doi: 10.1007/s11011-012-9287-9
187. Bremner JD, Wittbrodt MT, Gurel NZ, Shandhi MH, Gazi AH, Jiao Y, et al. Transcutaneous cervical vagal nerve stimulation in patients with posttraumatic stress disorder (PTSD): A pilot study of effects on PTSD symptoms and interleukin-6 response to stress. *J Affect Disord Rep.* (2021) 6:100190. doi: 10.1016/j.jadr.2021.100190
188. Wu Z, Zhang X, Cai T, Li Y, Guo X, Zhao X, et al. Transcutaneous auricular vagus nerve stimulation reduces cytokine production in sepsis: An open double-blind, sham-controlled, pilot study. *Brain Stimulation.* (2023) 16:507–14. doi: 10.1016/j.brs.2023.02.008
189. Salama M, Akan A, Mueller MR. Transcutaneous stimulation of auricular branch of the vagus nerve attenuates the acute inflammatory response after lung lobectomy. *World J Surg.* (2020) 44:3167–74. doi: 10.1007/s00268-020-05543-w
190. Seitz T, Szeles JC, Kitzberger R, Holbik J, Grieb A, Wolf H, et al. Percutaneous auricular vagus nerve stimulation reduces inflammation in critical covid-19 patients. *Front Physiol.* (2022) 13:897257. doi: 10.3389/fphys.2022.897257
191. Tynan A, Brines M, Chavan SS. Control of inflammation using non-invasive neuromodulation: past, present and promise. *Int Immunol.* (2022) 34:119–28. doi: 10.1093/intimm/dxab073
192. Liu F-J, Wu J, Gong L-J, Yang H-S, Chen H. Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives. *Front Neurosci.* (2024) 18:1490300. doi: 10.3389/fnins.2024.1490300
193. Yang Y, Zhang R, Zhong Z, Li J, Feng Y. Efficacy of transauricular vagus nerve stimulation for the treatment of chemotherapy-induced painful peripheral neuropathy: a randomized controlled exploratory study. *Neurol Sci.* (2024) 45:2289–300. doi: 10.1007/s10072-023-07229-2
194. Falvey A. Vagus nerve stimulation and inflammation: expanding the scope beyond cytokines. *Bioelectronic Med.* (2022) 8:s42234–022-00100-3. doi: 10.1186/s42234-022-00100-3
195. Bazoukis G, Stavrakis S, Armondas AA. Vagus nerve stimulation and inflammation in cardiovascular disease: A state-of-the-art review. *J Am Heart Assoc.* (2023) 12:e030539. doi: 10.1161/JAHA.123.030539
196. Thompson SL, O'Leary GH, Austelle CW, Gruber E, Kahn AT, Manett AJ, et al. A review of parameter settings for invasive and non-invasive vagus nerve stimulation (VNS) applied in neurological and psychiatric disorders. *Front Neurosci.* (2021) 15:709436. doi: 10.3389/fnins.2021.709436
197. Forte G, Troisi G, Pazzaglia M, Pascalis VD, Casagrande M. Heart rate variability and pain: A systematic review. *Brain Sci.* (2022) 12:153. doi: 10.3390/brainsci12020153
198. Kaniusas E, Kampusch S, Tittgemeyer M, Panetos F, Gines RF, Papa M, et al. Current directions in the auricular vagus nerve stimulation I – A physiological perspective. *Front Neurosci.* (2019) 13:854. doi: 10.3389/fnins.2019.00854
199. Butt MF, Albusoda A, Farmer AD, Aziz Q. The anatomical basis for transcutaneous auricular vagus nerve stimulation. *J Anat.* (2020) 236:588–611. doi: 10.1111/joa.13122
200. Matsuoka M, Yamaguchi T, Fujiwara T. Transcutaneous auricular vagus nerve stimulation in healthy individuals, stroke, and Parkinson's disease: a narrative review of safety, parameters, and efficacy [Review]. *Front Physiol.* (2025) 16:1693907. doi: 10.3389/fphys.2025.1693907
201. Kim AY, Marduy A, de Melo PS, Gianlorenco AC, Kim CK, Choi H, et al. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. *Sci Rep.* (2022) 12:22055. doi: 10.1038/s41598-022-25864-1
202. Austelle CW, Sege CT, Kahn AT, Gregoski MJ, Taylor DL, McTeague LM, et al. Transcutaneous auricular vagus nerve stimulation attenuates early increases in heart rate associated with the cold pressor test. *Neuromodulation.* (2024) 27:1227–33. doi: 10.1016/j.neurom.2023.07.012
203. Monti DA, Wintering N, Vedaei F, Steinmetz A, Mohamed FB, Newberg AB. Changes in brain functional connectivity associated with transcutaneous auricular vagus nerve stimulation in healthy controls [Original Research]. *Front Hum Neurosci.* (2025) 19:1531123. doi: 10.3389/fnhum.2025.1531123
204. Yokota H, Edama M, Kawanabe Y, Hirabayashi R, Sekine C, Akuzawa H, et al. Effects of transcutaneous auricular vagus nerve stimulation at left cymba concha on experimental pain as assessed with the nociceptive withdrawal reflex, and correlation with parasympathetic activity. *Eur J Neurosci.* (2024) 59:2826–35. doi: 10.1111/ejn.16305
205. Phillips I, Johns MA, Pandža NB, Calloway RC, Karuzis VP, Kuchinsky SE. Three hundred hertz transcutaneous auricular vagus nerve stimulation (taVNS) impacts pupil size non-linearly as a function of intensity. *Psychophysiology.* (2025) 62:e70011. doi: 10.1111/psyp.70011
206. Deligiannidis KM, Robakis T, Homitsky SC, Ibroci E, King B, Jacob S, et al. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder with peripartum onset: A multicenter, open-label, controlled proof-of-concept clinical trial (DELOS-1). *J Affect Disord.* (2022) 316:34–41. doi: 10.1016/j.jad.2022.07.068
207. Mao Y, Chen C, Falahpour M, MacNiven KH, Heit G, Sharma V, et al. Effects of sub-threshold transcutaneous auricular vagus nerve stimulation on cingulate cortex and insula resting-state functional connectivity. *Front Hum Neurosci.* (2022) 16:862443. doi: 10.3389/fnhum.2022.862443
208. Marsal S, Corominas H, de Agustín JJ, Pérez-García C, López-Lasanta M, Borrell H, et al. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. *Lancet Rheumatol.* (2021) 3:e262–9. doi: 10.1016/s2665-9913(20)30425-2
209. Gentile F, Giannoni A, Navari A, Degl'Innocenti E, Emdin M, Passino C. Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure. *Clin Autonomic Res.* (2025) 35:75–85. doi: 10.1007/s10286-024-01074-9
210. Zhang S, Zhao Y, Qin Z, Han Y, He J, Zhao B, et al. Transcutaneous auricular vagus nerve stimulation for chronic insomnia disorder: A randomized clinical trial. *JAMA Network Open.* (2024) 7:e2451217. doi: 10.1001/jamanetworkopen.2024.51217
211. Ackland GL, Patel ABU, Miller S, Gutierrez del Arroyo A, Thirugnanasambanthar J, Ravindran JI, et al. Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial. *Eur Heart J.* (2025) 46:1634–44. doi: 10.1093/eurheartj/ehaf037
212. Hatik SH, Arslan M, Demirbilek Ö, Özden AV. The effect of transcutaneous auricular vagus nerve stimulation on cycling ergometry and recovery in healthy young individuals. *Brain Behav.* (2023) 13:e3332. doi: 10.1002/brb3.3332
213. Bremner JD, Gurel NZ, Jiao Y, Wittbrodt MT, Levantsevych OM, Huang M, et al. Transcutaneous vagal nerve stimulation blocks stress-induced activation of Interleukin-6 and interferon- γ in posttraumatic stress disorder: A double-blind, randomized, sham-controlled trial. *Brain Behav Immun Health.* (2020) 9:100138. doi: 10.1016/j.bbih.2020.100138
214. Yang X, Wei M, Jiao Y, Xue X, Liu Y, Li R, et al. Site-specific stimulation imperative: lessons from a failed auricular-cervical transcutaneous vagus nerve stimulation comparison using closely matched parameters. *Brain Stimulation.* (2025) 19(2):103022. doi: 10.1016/j.brs.2025.103022
215. Drewes AM, Brock C, Rasmussen SE, Møller HJ, Brock B, Deleuran BW, et al. Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: results of a pilot study. *Scand J Rheumatol.* (2021) 50:20–7. doi: 10.1080/03009742.2020.1764617
216. Brock C, Rasmussen SE, Drewes AM, Møller HJ, Brock B, Deleuran B, et al. Vagal nerve stimulation-modulation of the anti-inflammatory response and clinical outcome in psoriatic arthritis or ankylosing spondylitis. *Mediators Inflamm.* (2021) 2021:9933532. doi: 10.1155/2021/9933532
217. Shi X, Hu Y, Zhang B, Li W, Chen JD, Liu F. Ameliorating effects and mechanisms of transcutaneous auricular vagus nerve stimulation on abdominal pain and constipation. *JCI Insight.* (2021) 6:1–18. doi: 10.1172/jci.insight.150052
218. de Moraes TL, Costa FO, Cabral DG, Fernandes DM, Sangaletti CT, Dalboni MA, et al. Brief periods of transcutaneous auricular vagus nerve stimulation improve autonomic balance and alter circulating monocytes and endothelial cells in patients with metabolic syndrome: a pilot study. *Bioelectron Med.* (2023) 9:7. doi: 10.1186/s42234-023-00109-2
219. Huguenard AL, Tan G, Rivet DJ, Gao F, Johnson GW, Adamek M, et al. Auricular vagus nerve stimulation for mitigation of inflammation and vasospasm in subarachnoid hemorrhage: a single-institution randomized controlled trial. *J Neurosurg.* (2025) 142:1720–31. doi: 10.3171/2024.10.Jns241643
220. Laurido-Soto OJ, Tan G, Nielsen SS, Huguenard AL, Donovan KM, Xu I, et al. Transcutaneous auricular vagus nerve stimulation reduces inflammatory biomarkers after large vessel occlusion stroke: results of a prospective randomized open-label blinded endpoint trial. *Trans Stroke Res.* (2025) 17:7. doi: 10.1007/s12975-025-01405-6
221. Corrêa FI, Souza PHL, Uehara L, Ritti-Dias RM, Oliveira da Silva G, Segheto W, et al. Transcutaneous auricular vagus nerve stimulation improves inflammation but does not interfere with cardiac modulation and clinical symptoms of individuals with COVID-19: A randomized clinical trial. *Life.* (2022) 12:1644. doi: 10.3390/life12101644
222. Yeom JW, Kim H, Park S, Yoon Y, Seo JY, Cho C-H, et al. Transcutaneous auricular vagus nerve stimulation (taVNS) improves sleep quality in chronic insomnia disorder: A double-blind, randomized, sham-controlled trial. *Sleep Med.* (2025) 133:106579. doi: 10.1016/j.sleep.2025.106579
223. Tan C, Qiao M, Ma Y, Luo Y, Fang J, Yang Y. The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: A systematic review and meta-analysis of randomized controlled trials. *J Affect Disord.* (2023) 337:37–49. doi: 10.1016/j.jad.2023.05.048
224. Li S, Rong P, Wang Y, Jin G, Hou X, Li S, et al. Comparative effectiveness of transcutaneous auricular vagus nerve stimulation vs citalopram for major depressive disorder: A randomized trial. *Neuromodulation.* (2022) 25:450–60. doi: 10.1016/j.neurom.2021.10.021
225. Liu C, Tang H, Liu C, Ma J, Liu G, Niu L, et al. Transcutaneous auricular vagus nerve stimulation for post-stroke depression: A double-blind, randomized, placebo-controlled trial. *J Affect Disord.* (2024) 354:82–8. doi: 10.1016/j.jad.2024.03.005
226. Ferreira LMA, Brites R, Fraião G, Pereira G, Fernandes H, De Brito JAA, et al. Transcutaneous auricular vagus nerve stimulation modulates masseter muscle activity, pain perception, and anxiety levels in university students: a double-blind, randomized, controlled clinical trial. *Front Integr Neurosci.* (2024) 18:1422312. doi: 10.3389/fnint.2024.1422312

227. Bremner JD, Gurel NZ, Wittbrodt MT, Shandhi MH, Rapaport MH, Nye JA, et al. Application of noninvasive vagal nerve stimulation to stress-related psychiatric disorders. *J Personal Med.* (2020) 10:119. doi: 10.3390/jpm10030119
228. Goadsby P, Grosberg B, Mauskop A, Cady R, Simmons K. Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. *Cephalalgia.* (2014) 34:986–93. doi: 10.1177/0333102414524494
229. Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, et al. Non-invasive vagus nerve stimulation for the ACute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. *Headache: J Head Face Pain.* (2016) 56:1317–32. doi: 10.1111/head.12896
230. Tassorelli C, Grazi L, De Tommaso M, Pierangeli G, Martelletti P, Rainero I, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. *Neurology.* (2018) 91:e364–e373. doi: 10.1212/WNL.0000000000005857
231. Costa V, Gianlrenço AC, Andrade MF, Camargo L, Menacho M, Arias Avila M, et al. Transcutaneous vagus nerve stimulation effects on chronic pain: systematic review and meta-analysis. *Pain Rep.* (2024) 9:e1171. doi: 10.1097/PR9.0000000000001171
232. Laqua R, Leutzow B, Wendt M, Usichenko T. Transcutaneous vagal nerve stimulation may elicit anti- and pro-nociceptive effects under experimentally-induced pain — A crossover placebo-controlled investigation. *Autonomic Neurosci.* (2014) 185:120–2. doi: 10.1016/j.autneu.2014.07.008
233. Zuo X, Xu Y, Li S, Jiang J, Wang J, Zhu Y, et al. Efficacy and safety of transcutaneous auricular vagus nerve stimulation plus pregabalin for radiotherapy-related neuropathic pain in patients with head and neck cancer (RELAX): a phase 2 randomised trial. *EClinicalMedicine.* (2025) 86:103345. doi: 10.1016/j.eclinm.2025.103345
234. Aranow C, Atish-Fregoso Y, Lesser M, Mackay M, Anderson E, Chavan S, et al. Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. *Ann Rheum Dis.* (2021) 80:203–8. doi: 10.1136/annrheumdis-2020-217872
235. McIntire LK, McKinley RA, Goodyear C, McIntire JP, Brown RD. Cervical transcutaneous vagal nerve stimulation (ctVNS) improves human cognitive performance under sleep deprivation stress. *Commun Biol.* (2021) 4:634. doi: 10.1038/s42003-021-02145-7
236. Yin Y, Li Z, Lyu B, Deng H, Wang J, Hou B, et al. The role of transcutaneous vagal nerve stimulation in cancer-related fatigue and quality of life in breast cancer patients receiving radiotherapy: A randomized, double-blinded and placebo-controlled clinical trial. *Int J Radiat OncologyBiologyPhysics.* (2022) 114:S6–7. doi: 10.1016/j.ijrobp.2022.07.341
237. De Couck M, Caers R, Spiegel D, Gidron Y. The role of the vagus nerve in cancer prognosis: A systematic and a comprehensive review. *J Oncol.* (2018) 2018:1236787. doi: 10.1155/2018/1236787
238. Tsutsumi T, Ide T, Yamato M, Kudou W, Andou M, Hirooka Y, et al. Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction. *Cardiovasc Res.* (2008) 77:713–21. doi: 10.1093/cvr/cvm092
239. Ek M, Kurosawa M, Lundeberg T, Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1 β : role of endogenous prostaglandins. *J Neurosci.* (1998) 18:9471–9. doi: 10.1523/JNEUROSCI.18-22-09471.1998
240. Dubeykovskaya Z, Si Y, Chen X, Worthley DL, Renz BW, Urbanska AM, et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. *Nat Commun.* (2016) 7:10517. doi: 10.1038/ncomms10517
241. Reijmen E, Vannucci L, De Couck M, De Grève J, Gidron Y. Therapeutic potential of the vagus nerve in cancer. *Immunol Lett.* (2018) 202:38–43. doi: 10.1016/j.imlet.2018.07.006
242. Kumaria A, Ashkan K. Neuromodulation as an anticancer strategy. *Cancer Med.* (2023) 12:20521–2. doi: 10.1002/cam4.6624